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Abstract 
 
Chronic obstructive pulmonary disease (COPD) is characterized by irreversible airflow 
obstruction caused by airway remodelling and parenchymal destruction. Clinically, 
observation of COPD is performed using spirometry, but this technique only provides a global 
measure of lung health. To supplement these clinical measurements, thoracic computed 
tomography (CT) and hyperpolarized gas magnetic resonance imaging (MRI) have been used 
to measure regional structure and function abnormalities. Although CT and MRI have been 
used to research COPD, combination of both modalities into an interrelated image has never 
been performed. Therefore, we developed an image processing pipeline to combine MRI-CT 
information into a multi-parametric response map. In a COPD cohort, multi-parametric 
measurements became more abnormal as disease severity increased, were related to pulmonary 
function and quality of life, and revealed novel disease labels. This technique has potential to 
visualize and quantify the transition phases of COPD allowing for the possible identification 
of new treatment targets. 
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Summary for Lay Audience 
 
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide. 
Presently, there is no cure for COPD so treatment focuses on alleviating symptoms, reducing 
exacerbations and hospitalizations, and improving quality of life. COPD is diagnosed and 
monitored using spirometry, a method for measuring airflow at the mouth. While spirometry 
is widely available and easy to use, it provides only a global measurement of lung function and 
cannot provide any regional information about the underlying abnormalities present within 
patients’ lungs.  
To supplement spirometry, medical imaging has been used to provide regional measurements 
as well as information about the underlying abnormalities present within the lungs. Two 
imaging techniques used in studying COPD are x-ray computed tomography (CT) and 
hyperpolarized gas magnetic resonance imaging (MRI). Chest CT is used to measure structural 
changes within the lungs such as tissue destruction and airway abnormalities; whereas 
hyperpolarized gas MRI measures lung function by using an inhaled gas to identify 
unventilated regions of the lung known as ventilation defects. Typically, research in COPD 
uses either CT or MRI, but never a combination of the two in a single complementary image.  
In this study, we developed a technique to combine information from both CT and MRI into a 
single lung map and used this map to categorize patient with COPD. We observed that 
combined CT-MRI labels became more abnormal with increasing disease severity, were 
associated with measurements of pulmonary function, quality of life, and exercise capacity, 
and visualized possible transitory phases of COPD. This study is the first to use a combined 
CT-MRI label map approach in the investigation of COPD, and the visualization ability of this 
combined CT-MRI label map may allow for the identification of new treatment targets and 
endpoints.  
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CHAPTER 1 
 
1 INTRODUCTION 
Irreversible airflow obstruction due to parenchymal destruction, airway remodelling and 
luminal obstruction is the defining characteristic of chronic obstructive pulmonary disease 
(COPD). Imaging of COPD has focused on x-ray computed tomography (CT) or 
hyperpolarized gas magnetic resonance imaging (MRI) to measure the underlying 
pathophysiology and phenotype the disease, but no studies have investigated measurements 
obtained by combining information from both modalities. In this thesis, MRI and CT imaging 
measurements were combined to generate multi-parametric response maps (mPRM) and these 
maps were used to reveal phenotypes of COPD undetected using CT or MRI alone. 
1.1 Motivation and Rationale 
Chronic obstructive pulmonary disease (COPD) is a debilitating disease affecting 252 million 
people globally1 and constitutes the third leading cause of death worldwide.2 Figure 1-1 
highlights COPD as the most prominent cause of death compared to other chronic lung 
diseases. In addition to being a major contributor to worldwide mortality, this disease also 
constitutes a large healthcare burden. COPD exacerbations are the largest cause of prolonged 
hospital stays in Canada aside from giving birth,3 and these patients are more likely to be re-
admitted to hospital than any other chronic disease.4 In 2008, the direct cost of hospitalization 
in Canada from a COPD exacerbation was estimated at $10,000 per patient with combined 
costs of the disease totaling $1.5 billion every year.5 By 2011, this total severely 
underestimated the cost of COPD as the combined healthcare cost of this disease contributed 
about $3.9 billion in Ontario alone.6 
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Figure 1-1: Chronic Respiratory Disease Global Deaths. 
Amongst chronic respiratory diseases, COPD is the leading cause of death (n=3.2 million). 
Number of deaths are displayed using a logarithmic scale. This figure was adapted from GBD 
2017 Causes of Death Collaborators, Lancet (2018)2 
 
COPD is clinically diagnosed and monitored using pulmonary function tests due to their ease 
of use and extensive validation. Although these tests are the gold standard, they only provide 
a global measure of lung health and cannot determine the specific underlying pathophysiology 
in patients with similar outputs. To compensate for these limitations, x-ray computed 
tomography (CT) and hyperpolarized gas magnetic resonance imaging (MRI) have been used 
to collect regional structure and function information in the lungs. Pulmonary CT has been 
used to quantify lung structure abnormalities such as parenchymal destruction7 and airway 
remodelling,8 while hyperpolarized gas MRI has been used to provide lung function and 
structure measurements such as ventilation heterogeneity9 and airspace enlargement.10 This 
thesis focuses on the development and application of a multi-modality imaging method to 
combine pulmonary CT structure and MRI structure/function to phenotype COPD. 
 
This chapter provides the relevant background knowledge to understand the motivation for the 
original research provided in Chapter 2. In section (1.2), an overview of the respiratory 
system’s structure and function is presented, followed by the pathophysiology of COPD (1.3). 
Next, the current clinical measurements and diagnostic criteria of COPD (1.4) as well as 
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pulmonary imaging techniques (1.5) will be discussed. Finally, the hypotheses and objectives 
of this thesis will be stated (1.6). 
 
1.2 Structure and Function of the Lung 
The lung’s primary function is the transportation of oxygen to the bloodstream, and the 
removal of carbon dioxide from the body. To accomplish this task, the lung conducts air into 
the trachea, down the bronchi, through the bronchioles, into the alveolar ducts and ends in the 
alveoli where gas exchange occurs. 
1.2.1 Airways 
The airways are the main conduits of the respiratory system. As we move down the airway 
tree, the airways begin to bifurcate and increase in number. These smaller airways gradually 
decrease in diameter but increase in total cross-sectional area. Furthermore, the composition 
of the airway walls begins to change from cartilaginous to smooth muscle to epithelium as you 
progress more distally. The entire airway tree can be divided into the conducting zone and the 
respiratory zone (Figure 1-2). The conducting airways comprise the trachea, the bronchi and 
the terminal bronchioles, and contain only a small portion of the lung volume (approximately 
150 mL). The conducting zone is also known as “anatomic dead space” since it does not 
participate in gas exchange. Alternatively, the lung region that participates in gas exchange is 
called the respiratory zone. This area comprises the respiratory bronchioles, the alveolar ducts 
and the alveolar sacs. Since total cross-sectional area of all the airways increases further down 
the airway tree, this zone constitutes the majority of the lung volume (2.5 – 3.0 L).11  
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Figure 1-2: Schematic of an Idealized Human Airway Tree. 
Adapted from Respiratory Physiology: The Essentials 10th edition.11 
1.2.2 Parenchyma 
The primary function of the lung, gas exchange, occurs in tiny (0.3 mm in diameter) air sacs 
called alveoli. Within the respiratory zone, approximately 500 million alveoli11,12 are clustered 
together to create a very large surface area (approximately 85 m2) for gas exchange. The 
efficient architecture of the extremely thin alveolar walls (approximately 0.2-0.3 μm thick), 
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and the dense network of capillaries encompassing these alveoli allows for the near 
instantaneous exchange of oxygen and carbon dioxide with the bloodstream. 
 
1.3 Pathophysiology of Chronic Obstructive Pulmonary Disease 
COPD is defined by irreversible airflow obstruction caused by parenchymal destruction, 
airway remodelling, and luminal occlusion.13 These physiologic abnormalities are 
heterogeneously distributed throughout the lungs,14 and the extent of these abnormalities varies 
between people. The most common risk factor for developing COPD is the inhalation of 
noxious particles such as cigarette smoke, chemicals or inorganic dust, but other risk factors 
of the disease include a history of severe respiratory infection or genetic disorders such as 
alpha-1 antitrypsin deficiency.13 
 
Figure 1-3: Diagram of Pathologic Changes in COPD. 
Panels from left to right: normal small airway, normal lung parenchyma, emphysematous 
destruction of parenchyma, and remodelled airway with inflammatory exudates and thickened 
airway wall. Airway panels were adapted from Hogg (2004)15 and parenchyma panels were 
adapted from Woods et al. (2006).16 Permission to reproduce provided in Appendix C. 
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1.3.1 Emphysema 
Emphysema is characterized by parenchymal tissue destruction resulting in the permanent 
enlargement of the airspaces17,18 (Figure 1-3). The location and extent of parenchymal 
destruction varies between patients, but can be sub-classified into centrilobular, panlobular, 
paraseptal, and bullous emphysema.19 Centrilobular emphysema predominately affects the 
central part of the respiratory bronchioles leaving the alveoli unaffected and is associated with 
cigarette smoking. Conversely, panlobular emphysema affects both the respiratory bronchioles 
and the alveoli and is commonly observed in alpha-1 antitrypsin deficiency patients. Finally, 
paraseptal emphysema affects the lung tissue near the pleural septa. As emphysema progresses, 
the increased tissue destruction forms large airspaces known as bulla (bullous emphysema). In 
COPD, this destruction of parenchymal tissue reduces the surface area of the lungs needed for 
gas exchange as well as causes narrowing of the airways through loss of radial traction.20 
1.3.2 Airway Remodeling 
Airway remodeling is caused by chronic inflammation and mucus plugging commonly 
associated with chronic bronchitis (Figure 1-3). Excessive mucus secretion in the airways 
combined with inflammatory exudates form semi-solid plugs that occlude smaller bronchioles. 
Additionally, the repeated inflammation of the airways leads to a narrowing of the small 
airways due to cellular infiltration thickening the airway wall, increases in smooth muscle, and 
fibrotic restriction of airway enlargement.15,20,21 This remodeling process either occludes the 
airways thereby reducing the number of alveoli able to participate in gas exchange, or narrows 
the airways substantially that closure occurs during exhalation trapping air in the lungs (gas-
trapping). 
 
The majority of airway obstruction occurs in the small airways (< 2 mm diameter).22-24 Since 
these small airways have a large total cross-sectional area and only account for a small portion 
of total airway resistance, obstructions in these airways have little impact on total airway 
resistance making them relatively invisible on spirometry and allowing them to accumulate 
undetected in these airways over a long time.22 More recently, the obstruction of the small 
airways termed small airways disease has been observed to precede emphysematous 
destruction of the lung.25,26 
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1.4 Clinical Measures of Global Lung Function 
The gold standard for diagnosing and assessing COPD is pulmonary function testing. These 
tests provide an overall measure of lung health and function and are used to quantify disease 
progression and treatment efficacy. Pulmonary function tests include spirometry, 
plethysmography, and the diffusing capacity of the lung for carbon monoxide (DLCO). The 
assessments provided by these tests are commonly presented as a percent of the predicted value 
calculated from the patient’s age, sex, height, and ethnicity.27 
1.4.1 Spirometry 
Spirometry is the simplest of the pulmonary function tests to perform and can be administered 
using a handheld device as shown in Figure 1-4. This test is performed by having the patient 
make at tight seal around the mouthpiece and begin breathing normally though the device. 
After a couple of normal breaths, the patient inhales to total lung capacity (TLC) then forcefully 
exhales until no more air can be expelled.28 The volume of air the patient can expel from TLC 
in 1 second is known as the forced expiratory volume in 1 second (FEV1), and the volume 
expelled from TLC to full exhalation is known as the forced vital capacity (FVC).  
 
Figure 1-4: Handheld Spirometer and Volume-time Curve Used to Measure FEV1 and FVC. 
FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity 
 
These two measures, FEV1 and FVC, are used to clinically diagnose COPD. In COPD, there 
is a reduction in both FEV1 and FVC due to increased airway resistance and early airway 
 
8 
 
closure respectively. A ratio of FEV1/FVC < 0.70 post-bronchodilator is the clinical definition 
of COPD according to the Global initiative for chronic Obstructive Lung Disease (GOLD) 
criteria.13 Once the presence of COPD has been established, FEV1 percent predicted is used to 
determine severity as seen in Table 1-1. 
 
Table 1-1: COPD Severity Based on GOLD Criteria 
In patients with FEV1/FVC < 0.70: 
GOLD I        Mild FEV1 %pred ≥ 80% 
GOLD II       Moderate 50% ≤ FEV1 %pred < 80% 
GOLD III      Severe 30% ≤ FEV1 %pred < 50% 
GOLD IV      Very Severe FEV1 %pred < 30% 
 
1.4.2 Plethysmography 
Plethysmography calculates different lung volumes using Boyle’s Law.29 The lung volumes 
measured include functional residual capacity (FRC), total lung capacity (TLC) and residual 
volume (RV). FRC is the lung volume present after exhalation during normal breathing, TLC 
is the maximum lung volume attainable through inhalation, and RV is the minimum lung 
volume remaining after exhalation. From these three volumes, the inspiratory capacity (IC) 
and vital capacity (VC) can be calculated. The IC measures the maximum volume inspired 
from FRC and the VC is the maximum volume inspired from RV. Tidal volume (TV) is the 
volume inspired during normal breathing (figure 1-5).  
 
This measurement is performed in a sealed chamber known as a body plethysmograph. The 
patient sits upright inside the sealed chamber and performs a set of breathing maneuvers. The 
test starts with the patient breathing normally, and when the patient reaches near FRC, a shutter 
closes in the mouthpiece. The patient lightly pants into the shuttered mouthpiece for a few 
seconds then the shutter opens and the patient inhales to TLC and exhales to RV. From these 
breathing maneuvers, changes in pressure at the mouthpiece and inside the chamber can be 
used to calculate FRC from Boyle’s law since the volume of the sealed chamber is known. In 
COPD, these lung volumes are elevated due to gas-trapping in the lungs. 
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Figure 1-5: Body Plethysmograph and Volume-time Curve Used to Measure Lung Volumes. 
RV: residual volume; FRC: functional residual capacity; TV: tidal volume; IC: inspiratory 
capacity; VC: vital capacity; TLC: total lung capacity. 
 
1.4.3 Diffusing Capacity of the Lung for Carbon Monoxide 
Diffusing capacity of the lung for carbon monoxide (DLCO) can be used to probe alveolar tissue 
integrity in patients with emphysema. This test is performed by having the patient first exhale 
to RV, then inhale a specific gas mixture containing a small amount of carbon monoxide 
(0.3%) to TLC. At TLC, the patient holds their breath for 10 seconds allowing for the carbon 
monoxide to diffuse into the blood stream and then exhales. The difference in the concentration 
of carbon monoxide between the inhaled and exhaled gas mixtures is used to calculate the 
amount of gas that diffused into the blood stream.30 DLCO is reduced in COPD due to 
emphysema decreasing the surface area for gas exchange as well as airway occlusions blocking 
the gas mixture from reaching the alveoli. 
 
1.5 Imaging Pulmonary Structure and Function 
Although widespread, validated, and clinically diagnostic, pulmonary function tests provide 
only information about the global health of the lung and are not sensitive to regional changes.31 
To supplement these measurement, pulmonary imaging provides regional information about 
the lungs and assists in quantifying underlying pathophysiology. Pulmonary imaging can be 
broadly divided into structural and functional components. Lung structure has been imaged 
using CT, and ultra-short echo time (UTE) MRI, and provides measurements of 
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emphysema,7,32 gas-trapping,33,34 and airway architecture.8,35 Lung function can be assessed 
through multiple imaging modalities such as single-photon emission computed tomography 
(SPECT), CT, and MRI, and these modalities focus on ventilation within the lungs.36-38 As 
mentioned in Section 1.1, this thesis focuses on the development of a multi-modality structure-
function map in COPD. In this section, I highlight the diverse pulmonary imaging techniques 
used in studying COPD and provide some of their applications in COPD for possible use in 
expansion of the method presented in this thesis. 
1.5.1 Structural Imaging 
Advances in medical imaging has allowed for the non-invasive monitoring of changes in lung 
tissue and identification of anatomical abnormalities. The changes in lung tissue include airway 
remodelling through airway wall thickening or bronchiole destruction and parenchymal 
changes through emphysema or fibrosis. 
Computed Tomography 
CT was developed in the 1970s and has become the imaging modality of choice when assessing 
pulmonary diseases. Three-dimensional volumes are generated by acquiring multiple x-ray 
images at various angles as the x-ray source and detector are rotated around the patient, and 
these 2-D x-ray images are reconstructed into a 3D volume. Tissue density in these images is 
measured in Hounsfield Units (HU), a measurement of an object’s density relative to water,39 
and is calculated using the equation below: 
 
𝐻𝑈 = (
𝜇𝑇𝑖𝑠𝑠𝑢𝑒 − 𝜇𝑊𝑎𝑡𝑒𝑟
𝜇𝑊𝑎𝑡𝑒𝑟
) 𝑥 1000 
 
where the linear attenuation coefficients for the tissue of interest is μtissue and water is μwater. 
The dynamic range of this measurement transitions from bone (1000 HU) to water (0 HU) to 
air (-1000 HU) with all other tissue falling in between. From these density measurements, 
tissue abnormalities in the lung such as emphysema and gas-trapping can be measured. With 
emphysema, the destruction of the surrounding tissue creates large pockets of air in the lungs 
thereby reducing the tissue density in those regions. This reduction in tissue density creates 
low attenuating regions on CT with HU values similar to air. In COPD, these low attenuating 
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areas can be quantified on inspiratory CT as a measure of the extent of emphysema in the lungs. 
Figure 1-6 visualizes these low attenuating regions as dark patches on CT and highlights the 
extent of emphysema within the lungs in yellow. Commonly set thresholds for emphysema 
include -910 HU,40 -950 HU,7 and -960 HU.41 Additionally, gas-trapping is similarly measured 
as low attenuating areas on full expiratory CT due to airway closures trapping air within the 
lungs. A commonly used threshold of gas-trapping is -856 HU.42,43  
 
In addition to measuring tissue integrity, the airway tree can be segmented using CT analysis 
packages such as VidaVision (Vida Diagnostics, Coralville, IA, USA), Pulmo3D (Fraunhofer 
MEVIS, Bremen, Germany) or thoracic VCAR (General Electric Healthcare, Milwaukee, WI, 
USA). The number of airway generations visible is limited by the resolution of the CT images, 
but typically it can be segmented down to the beginning of the small airways (<2 mm 
diameter). From these trees, airway measurements such as wall area percent, wall thickness, 
and lumen area can be used to assess the narrowing of the small airways. The thickening of the 
airway walls and reduction of the lumen area have been associated with a decline in pulmonary 
function,8,44 increased prevalence of symptoms,45 and progression of COPD.25 Additionally, 
the loss of peripheral airways21,22 and reduction in total airway count46 have also been 
associated with disease progression.25,26 
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Figure 1-6: Computed Tomography Images of COPD. 
Top: coronal centre slices for healthy, mild and severe COPD. Low attenuating areas (RA950) 
indicative of emphysema are highlighted in yellow. Bottom: 3D models of CT airway trees. 
 
Ultra-short Echo Time MRI 
While CT provides many structural measurements of the lung, the main disadvantage of this 
technique is the radiation dose to the patient which limits its uses. MRI on the other hand has 
no dose concerns but suffers from low signal in the lungs.  The low signal stems from a low 
proton density present within the lung tissue and local magnetic field susceptibility at the air-
tissue interfaces leading to fast signal decay.47,48 By shortening the echo time required, 
improved k-space acquisition techniques such as ultra-short echo time (UTE) and more 
recently zero echo time (ZTE)49 are able to minimize the signal lost through decay. These 
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techniques have provided measures of tissue density that correlate well with CT measures of 
emphysema,48,50 CT functional lung volume47,51 and pulmonary function in COPD47,51  as well 
as provided similar structural measurements as low-dose CT without the radiation dose.32 
1.5.2 Functional Imaging 
In contrast to measuring structural changes, functional imaging identifies defects in the lungs 
by mimicking respiration. These techniques can be broadly divided into two groups depending 
on whether or not inhaled gas contrast agents are used. 
Xenon Enhanced Dual Energy CT 
Xenon enhanced dual energy CT leverages the different attenuation properties of xenon at high 
and low photon energies to separate it from the surrounding air and soft tissue. Using this 
difference, xenon can work as an inhaled contrast agent to measure ventilation in the lungs. 
This is performed by having the patient wear a secured positive-pressure ventilation facemask 
and breathing a 30%/70% xenon/oxygen mixture until the lungs are filled with 30% xenon. 
Once this point is reached, simultaneous acquisitions from two x-ray sources occur allowing 
for three-material decomposition to separate the xenon signal from the surrounding air and 
tissue.52 This technique has been applied to COPD37,53-55 and other pulmonary diseases.56-58 In 
COPD, low attenuating regions on CT retained xenon during dynamic washout53 and xenon 
ventilation correlated with pulmonary function.37,54 Although research into this imaging 
technique has provided measures of lung ventilation in COPD, a few limitations, such as xenon 
inhalation side effects, radiation exposure, and cost, still need to be addressed. 
Four-Dimensional X-ray Computed Tomography (4DCT) 
In addition to using inhaled xenon to assess lung ventilation, regional volume changes during 
the respiratory cycle can be used as a surrogate for lung ventilation.59-63 This surrogate 
measurement follows the assumption that healthy lung will have a large change in volume 
while gas-trapping and restricted areas will have a small change in volume with the respiratory 
cycle. To measure this volume change, an imaging technique known as four-dimensional CT 
(4DCT) acquires multiple CT images throughout the respiratory cycle. These images are 
binned into specific respiratory phases, and expiratory and inspiratory images are co-registered 
together. After co-registration, the voxel deformations are used to calculate this surrogate 
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measure of ventilation. This technique has shown reasonable correlation with xenon enhanced 
CT60 and SPECT ventilation.62,63 Current implementation of this technique has been focused 
in lung cancer. CT ventilation in these patients has correlated with pulmonary function,64,65 
and is reduced in areas of emphysema.66 Since lung cancer is commonly co-morbid in COPD, 
similar results with pulmonary function and emphysema are expected. Although 4DCT 
provides reasonable measures of ventilation, artifacts stemming from the binning process or 
registration have a major effect on lung ventilation.62,63 
Parametric Response Mapping 
Another surrogate functional imaging technique, parametric response mapping (PRM), uses 
co-registered inspiratory and expiratory CT images to classify lung tissue based on the 
presence of air. This voxel-wise mapping technique was first introduced using MRI measures 
of water diffusion and relative blood volume and flow to detect treatment efficacy in 
glioblastomas67,68 and later applied to thoracic CT for phenotyping disease severity in COPD.69 
This technique labels spatially co-registered voxels using tissue density thresholds of 
emphysema (<-950 HU on inspiratory)7 and gas-trapping (<-856 HU on expiratory).42 The 
lung tissue is divided into three groups based on these thresholds: normal, functional small 
airways disease, and emphysema. As seen in Figure 1-7, normal (green) tissue is defined as 
any co-registered voxel with a value that is greater than both the inspiratory and expiratory 
thresholds. Functional small airways disease (yellow) tissue is defined as any voxel that is 
greater than the inspiratory threshold but less than the expiratory threshold. This classification 
indicates early closure of the airways during exhalation leading to gas-trapping in the lungs. 
Finally, emphysema (red) tissue is defined as any voxel that is less than both the inspiratory 
and expiratory thresholds. Voxels that are less than the inspiratory threshold and greater than 
the expiratory threshold indicate noise within the images. In studies of participants with COPD, 
PRM measurements were correlated with pulmonary function,69,70 determined presence of 
COPD in current and former smokers,71 and were associated with decline in FEV1.
72 
Additionally, PRM measures of functional small airways disease predicted patient 
survivability after lung transplant,73 and more recently have been histologically validated as an 
imaging measure of small airways disease in severe COPD.74 This technique has also provided 
imaging evidence to the idea that small airways disease precedes emphysema in the 
progression of COPD.25,26,69,75    
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Figure 1-7: Diagram for Paired Inspiratory/Expiratory CT Parametric Response Mapping. 
Spatially registered voxels (left) are labeled based on CT densities (centre) to generate a 
functional map of the tissue (right). 
 
Single-Photon Emission Computed Tomography (SPECT) 
SPECT uses inhaled radioactive tracers that emit high energy photons (gamma rays) when they 
decay. After the inhalation of the tracer, multiple images are acquired from a single or multiple 
gamma cameras rotating around the patient to collect the gamma rays. These images are then 
reconstructed to generate a three dimensional volume of the radioactivity. The commonly 
inhaled radioactive tracers to generate ventilation images are gaseous 81mKr, 133Xe, or an 
ultrafine aerosol 99mTc-labeled carbon (“Technegas”). In COPD, SPECT ventilation has a 
longer washout time in areas of emphysema,76 and correlates with pulmonary function.77 It has 
also shown ventilation and gas-trapping in emphysematous bullae78 and correlation with 
disease severity.77,79 
Oxygen Enhanced MRI 
In order to reduce radiation exposure during functional imaging, new MRI techniques have 
been developed. These techniques use non-radioactive inhaled gas contrast to mimic inhaled 
air and highlight functioning tissue. Oxygen enhanced MRI as a functional imaging technique 
was first developed in 1996.80 This technique leveraged the weakly paramagnetic properties of 
oxygen and the large surface area of the lungs to increase MRI signal in the parenchyma. 
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Ventilation of the lungs is calculated by acquiring T1-weighted proton images at baseline (21% 
oxygen saturation) and oxygen enhanced (100% oxygen saturation) and finding the relative 
change in signal intensity for each voxel between the oxygen enhanced image and the baseline 
room air image. In COPD, this oxygen enhancement ratio  has shown correlation with diffusing 
capacity,81,82 CT measures of emphysema,82 post-treatment clinical outcomes,83 and 
pulmonary function loss and disease severity.84,85 
Hyperpolarized Gas MRI 
Hyperpolarized gas MRI uses noble gases such as 3He and 129Xe as an inhaled contrast agent 
to visualize the regional ventilation of the lungs. Due to the low density of atoms in gases, 
these gases must be hyperpolarized to increase their MR signal. To polarize these gases, spin-
exchange from a laser-based optical pumping technique is used.86,87 Briefly, alkali metal vapor 
(typically Rubidium) absorbs circularly polarized laser light. Collisions between the vaporized 
metal and the noble gas transfers the stored angular momentum from the vaporized metal to 
the noble gas nucleus. This transfer of angular momentum flips the spin of the unpaired proton 
in the noble gas. This optical pumping technique allows for an increase in the signal of the gas 
by 5 orders of magnitude compared to its thermal equilibrium value.86 Hyperpolarized gas 
imaging of the lungs started in 1994 using 129Xe.86 The field transitioned to 3He for its larger 
gyromagnetic ratio allowing for better signal-to-noise and improved polarization, but factors 
such as limited availability and increased cost of 3He as well as technological improvements 
in 129Xe polarization have led the field back to 129Xe again.88,89 
 
Hyperpolarized gas MRI allows for the visualization of functional lung regions through 
mimicking the movement of air into the lungs by inhaling the polarized gas. As seen in Figure 
1-8, the teal areas highlight functioning regions of the lung that the gas can travel to while the 
dark areas are unventilated regions of the lung known as ventilation defects. Quantification of 
non-functioning lung has been performed using the ratio of unventilated lung volume to total 
lung volume, known as ventilation defect percent (VDP).90 In COPD, this measure of 
ventilation is correlated with SPECT ventilation,36 related to disease severity,9 highly 
repeatable,91 related to pulmonary function,14,92 diffusing capacity,91 and CT measures of 
emphysema93 and gas-trapping,94 as well as improves with application of a bronchodilator.95 
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This imaging technique has also been used to predict exacerbations,93 longitudinal changes in 
quality of life,96 and visualize collateral ventilation in COPD.97 
 
Another imaging technique using hyperpolarized gas is diffusion weighted imaging. Diffusion 
weighted imaging takes advantage of the restricted Brownian motion of the gas within the 
lungs to provide a measure of tissue integrity known as the apparent diffusion coefficient 
(ADC). These ADC values are highly reproducible98-100 and are sensitive to regions of 
emphysema.10,16 This sensitivity comes from changes in alveolar dimensions caused by 
emphysema. In healthy tissue, the movement of the gas molecules is restricted by the airways 
and alveolar walls; while in emphysematous regions, destruction of these tissue structures 
allows the gas molecules to move around more freely. ADC measurements are also related to 
CT measures of emphysema,101-103 pulmonary function,102 diffusing capacity,101,103,104 quality 
of life,104,105 and are a sensitive measure of reduced exercise capacity in mild COPD.104,105 
While an important measure of emphysema, there are other factors that can influence ADC 
values such as gravity induced tissue compression,103,104,106,107 alveolar distension due to gas-
trapping,94,108 and age.109 
 
While 3He and 129Xe MRI provide important measures of lung function, there are some safety 
and imaging factors that need to be considered as the field transitions back to xenon. The use 
of xenon is well tolerated in patients, but there are some side effects such as dizziness, light-
headedness and euphoria due to the analgesic nature xenon.110,111 Although present, these side 
effects subside within a few minutes. With respect to imaging measures, 129Xe ventilation has 
greater defect volumes compared to 3He,91,92 which has been attributed to the lower diffusivity 
of xenon in air thereby preventing the gas from traveling through partially occluded airways 
within the timeframe of the breath hold scan. Additionally, these regions of unventilated lung 
on 129Xe are related to increased emphysema in those areas.112 Although hyperpolarized gas 
provides important measures, this modality is limited by high costs, specialized equipment and 
hardware, and clinical approval. 
 
18 
 
 
Figure 1-8: Hyperpolarized Gas MRI for Healthy and COPD Subjects. 
Top: 3He static ventilation for healthy and COPD subjects. The healthy subject has uniform 
ventilation throughout the lungs, while the COPD subjects have a more heterogeneous 
ventilation. 
Bottom: 3He ADC images for healthy and COPD subjects. The healthy subject has uniformly 
low ADC values indicating normal tissue integrity while the COPD subjects have higher ADC 
values indicating tissue destruction. 
 
Free-Breathing Fourier Decomposition Magnetic Resonance Imaging (FDMRI) 
Another proton-based functional imaging technique is Fourier decomposition MRI (FDMRI). 
Similar to 4DCT, FDMRI uses the deformation of lung tissue as a surrogate of ventilation. As 
air fills the lungs, tissue density decreases thereby reducing MR signal and voxel intensity. 
This technique uses multiple images of a single slice acquired over a time series during tidal 
breathing. These images are then non-rigidly registered together, and the changing voxel 
intensities from the tissue expansion and compression are used to create an oscillating signal 
for each voxel. A fast Fourier transform is applied to these oscillating signals to create a 
frequency spectrum. The peak amplitude at the respiratory frequency for each voxel is 
determined, and from these amplitudes, a ventilation weighted image is generated.113 FDMRI 
ventilation is consistent with hyperpolarized 3He114-116 and SPECT117 measures of ventilation, 
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and in COPD, FDMRI ventilation is correlated with pulmonary function118 while ventilation 
defects are correlated with airways resistance and CT measures of emphysema.114 
1.6 Thesis Hypotheses and Objectives 
COPD is diagnosed and monitored using spirometry. While this measurement is widely 
available and easy to use, it provides only a global assessment of lung health. Recently, CT 
and hyperpolarized gas MRI have been used to measure regional information about the lungs. 
Generally, imaging measurements of COPD have only focused on one of these imaging 
modalities and have not used both in combination. Therefore, the overarching objective of this 
thesis was to develop a multi-modality image processing pipeline to generate combined CT 
and MRI measurements in the form of a multi-parametric response map. To do this, 
hyperpolarized gas MRI and CT images were segmented and registered together. CT and MRI 
thresholds of normality were used to generate voxel-wise labels, and these labels were 
combined to create multi-parametric response maps. We hypothesized that combining MRI 
and CT measurements would reveal phenotypes of COPD that are undetected using MRI or 
CT alone. The objective of Chapter 2 was to develop a multi-modality image processing 
pipeline to combine CT and MRI measurements and to apply it to a cohort of COPD patients. 
 
In Chapter 3, I provide a summary of the important findings and conclusions from Chapter 2 
and discuss the limitations of this work. Finally, I conclude with some future directions to build 
upon the work presented in this thesis. 
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CHAPTER 2 
 
2 PULMONARY IMAGING PHENOTYPES OF CHRONIC 
OBSTRUCTIVE PULMONARY DISEASE USING MULTI-
PARAMETRIC RESPONSE MAPS 
 
2.1 INTRODUCTION 
In patients with chronic obstructive pulmonary disease (COPD), irreversible airflow 
obstruction related to parenchymal destruction, airway remodeling and luminal obstruction1 
drives debilitating symptoms, poor quality of life and premature death. While the forced 
expiratory volume in 1 second (FEV1) remains a key clinical and diagnostic measurement of 
COPD, it cannot provide regional information nor adequately discriminate between patients 
with different underlying pathologies such as airspace enlargement and small airways disease 
that present differently in individual patients. 
 
To address some of the limitations of spirometry measurements, thoracic x-ray CT has been 
used to provide quantitative airway2 and parenchyma3 information as well as indirect 
information related to small airways disease generated using parametric response maps 
(PRM).4-6 Pulmonary CT has been used widely in studies such as COPDGene,7 SPIROMICS,8 
MESA,9 CanCOLD10 and ECLIPSE.11 CT PRM quantifies COPD severity,4,12 monitors COPD 
progression13,14 and predicts post-transplant survival.6 
 
Hyperpolarized noble gas MRI has also been used to measure regional lung ventilation15 and 
airspace enlargement16,17 in patients with COPD.  MRI ventilation heterogeneity is quantified 
using ventilation defect percent, which is related to COPD severity and exacerbations.18 
Hyperpolarized 3He MRI apparent diffusion coefficients (ADC) may also be used in patients 
with COPD to estimate terminal airspace enlargement17 and such measurements have been 
histologically validated.19 
 
The Thoracic Imaging Network of Canada (TINCan)20 study acquired volume-matched CT 
and MRI in ex-smokers with and without COPD in whom spatial correlations between MRI 
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ventilation defects and non-contrast low-dose CT measurements of emphysema and airways 
disease were reported.18  CT PRM in TINCan participants also revealed spatial correlations 
between PRM measures of emphysema and gas-trapping with MRI values.21  In addition, in a 
small group of at-risk TINCan ex-smokers without CT evidence of emphysema and modestly 
abnormal diffusing capacity, there was abnormal MRI ADC, profound exercise limitation and 
diminished quality of life.22  Given the complementary nature of pulmonary CT and 
hyperpolarized gas MRI, we postulated that combining the information of these two modalities 
would provide new measures of lung abnormality not seen using CT or MRI alone.  Based on 
these previous findings, we hypothesized that by combining MRI and CT measurements using 
a multi-parametric voxel approach, phenotypes would be observed that are undetected using 
CT or MRI alone. The purpose of this study was to generate multi-parametric response map 
(mPRM) measurements in ex-smokers with and without COPD using volume-matched CT and 
hyperpolarized 3He MRI measurements acquired within a few minutes of one another. 
2.2 MATERIALS AND METHODS 
2.2.1 Study Participants and Design  
We evaluated ex-smokers with and without COPD who provided written informed-consent to 
a research ethics board approved (Institutional Ethics Board # 00000984) and HIPAA-
compliant, registered study (NCT02279329 clinicaltrials.gov). Participants were recruited 
from local tertiary care clinics and through advertisements as a convenience sample. Inclusion 
criteria for the study were men and women between 45-90 years of age, clinical diagnosis of 
COPD or >10 pack year smoking history, in stable health and ambulatory. Exclusion criteria 
included MRI contraindications, complete CT and MRI datasets missing or participants with 
bronchiectasis only (Figure 2-1). The study was prospectively planned and performed from 
December 2010 to January 2019; participants underwent a single two-hour visit and performed 
spirometry, plethysmography, quality of life questionnaires, exercise capacity tests, MRI and 
CT as previously described.20  Evaluations were performed 20 minutes after administering 
Novo-Salbutamol HFA using a metered-dose inhaler (four doses of 100 ug, Teva Novopharm 
Ltd., Toronto, ON, Canada) through a spacer (AeroChamber Plus spacer, Trudell Medical 
International, London, ON, Canada).  Participants in the TINCan study have been previously 
described.18,22-26 These prior articles dealt with a cross-sectional and longitudinal analysis of 
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the CT and MRI data and their relationships with quality of life, exacerbations and exercise 
capacity, whereas in this manuscript we report on the development of an mPRM approach and 
apply this to 175 TINCan participants who had complete image datasets required for the 
analysis.  Data generated during the study are available from the corresponding author and the 
mPRM method we developed is also available online (www.imaging.robarts.ca/parraga/). 
 
 
 
Figure 2-1. Participant Flowchart 
Flowchart showing the participants enrolled in the study. COPD=chronic obstructive 
pulmonary disease; mPRM=multi-parametric response maps. 
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2.2.2 Pulmonary Function and Quality of Life Tests 
Spirometry, plethysmography, and diffusing capacity of the lung for carbon monoxide (DLCO) 
were performed according to American Thoracic Society/European Respiratory Society 
guidelines27-29 using a body plethysmograph (MedGraphics Elite Series, MGC Diagnostic 
Corporation, St. Paul, MN) with an attached gas analyzer. The St. George’s Respiratory 
Questionnaire was administered,30 and a six-minute walk test  was performed.31 
2.2.3 MRI 
All MRI acquisitions were performed using methods that were previously described.20 Briefly, 
anatomical proton (1H), hyperpolarized 3He static ventilation, and diffusion weighted MRI 
were performed supine on a 3.0-T Discovery MR750 system (GE Healthcare, Milwaukee, WI) 
with broadband imaging capabilities. 1H MRI was acquired using a fast-spoiled gradient 
recalled echo sequence (FGRE) (TR/TE/flip angle = 4.7ms/1.2ms/30○) with a whole-body 
radio-frequency coil during a breath-hold after inhalation of 1.0-L of N2. 
 
3He polarization was performed to 30%-40% polarization and all 3He MRI was performed 
using a single-channel rigid elliptical transmit-receive chest coil (RAPID Biomedical, 
Wuerzburg, Germany) during a 1.0-L breath-hold of diluted hyperpolarized gas. 3He static 
ventilation was acquired using an FGRE sequence (TR/TE/flip angle = 4.3ms/1.4ms/7○) while 
diffusion-weighted 3He was acquired using an FGRE sequence (TR/TE/flip angle = 
7.6ms/3.7ms/8○) with and without diffusion sensitization with b = 1.6 s/cm2. A detailed 
description of the MRI acquisition parameters is provided in the Supplement. 
2.2.4 CT Imaging 
Within 30 minutes of the MRI, CT was acquired supine on a 64-slice Lightspeed VCT scanner 
(GE Healthcare) under breath-hold after inhalation of 1.0-L N2 from functional residual 
capacity using the following parameters: 64 x 0.625 mm, 120 kVp, 100 mA effective current, 
rotation time = 500 ms, and pitch = 1.0.22 Specific CT acquisition parameters are provided in 
the Supplement.  Total effective dose was estimated as 1.8 mSv using the ImPACT CT patient 
dosimetry calculator (based on Health Protection Agency [UK] NRBP-SR250). 
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2.2.5 Image Analysis 
MR and CT image segmentations were performed by a single observer (J.L.M with 1.5 years 
of experience).  3He and 1H MRI were semi-automatically segmented and co-registered using 
in-house software.21  Diffusion-weighted images were automatically processed to generate 
lung ADC images.21  CT images were segmented using Pulmonary Workstation 2.0 (VIDA 
Diagnostics, Coralville, IA).  Image registration of 3He ventilation, ADC, and CT images was 
performed using a custom algorithm in MATLAB R2018a (Mathworks, Natick, MA).  CT and 
1H MRI were non-rigidly registered using the modality-independent neighborhood-descriptor 
method;32 3He ventilation and ADC images were co-registered using intensity-based rigid 
registration. Image analysis specifics are provided in the Supplement. 
2.2.6 Development of Multi-Parametric Response Maps 
Once all the images were co-registered, voxels within the proton thoracic cavity were labelled 
to generate mPRM. These labels were generated based on ventilation, ADC values and CT 
density histogram threshold values as shown in Figure 2-2.  The CT threshold of -950 
Hounsfield units (HU) was used as a well-established and validated measure of emphysema in 
the lungs;3 whereas the ADC threshold of 0.30 cm2/s was based upon experimentally acquired 
ADC values reported in a group of elderly never-smokers. The threshold we used was equal to 
one standard deviation of the mean of this group, as a conservative estimate. ADC values for 
this group of never-smokers were previously reported.33 Although CT imaging was performed 
at functional residual capacity+1L, this lung volume is roughly 80-90% of total lung capacity 
in COPD patients, especially when supine in the scanner; moreover, Madani and colleagues34 
also previously reported that such differences related to lung volume are within a few percent 
for RA950 values and that these are unlikely to be clinically relevant.  Multi-parametric 
response maps were evaluated by a single observer (J.L.M). Figure 2-3 shows in schematic, 
for a representative Global initiative for chronic Obstructive Lung Disease (GOLD) III-IV ex-
smoker, the generation of mPRM values and the five resultant mPRM voxel classifications: 1) 
Normal in green, 2) Ventilated, CT ≥ -950 HU, Abnormal ADC in yellow, 3) Ventilated, CT 
Emphysema, Abnormal ADC in orange, 4) Not Ventilated, CT ≥ -950 HU, No ADC in red and 
5) Not Ventilated, CT Emphysema, No ADC in burgundy. ADC values reflect gas 
displacement but only in ventilated regions of the lung. Because CT and MR images were 
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acquired at the same lung volume, the potential for co-registration errors is low but not 
impossible. Hence, voxels labelled Ventilated, CT Emphysema, Normal ADC were classified 
as registration errors because of the high sensitivity of MRI to emphysema which suggests that 
normal ADC and CT emphysema are unlikely in the same voxel, although this finding may 
also stem from partial volume averaging. 
  
 
36 
 
Figure 2-2. Multi-parametric Response Map Thresholds and Decision Tree 
HU=Hounsfield unit; ADC=apparent diffusion coefficient 
Image Thresholds Image Voxel Classification 
 Normal Abnormal 
Inspiration CT density ≥ -950 HU < -950 HU 
MRI function Ventilated Not Ventilated 
MRI microstructure 0.0 < ADC <0.3 cm2/s Not ventilated OR ADC >0.3 cm2/s 
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Figure 2-3. Schematic for Multi-parametric (MRI and CT) Response Maps in COPD 
Top:  Co-registration of three contemporaneously acquired images of a GOLD III/IV ex-
smoker (CT, MRI ventilation, MRI ADC) into a single map. 
Bottom:  Three-dimensional mPRM voxel classification. Green=ventilated voxels, CT ≥ -950 
HU and normal ADC; Yellow=ventilated voxels, CT ≥ -950 HU and abnormal (>0.30cm2/s) 
ADC; Orange=ventilated voxels, CT emphysema and abnormal ADC; Red voxels=not 
ventilated, CT ≥ -950 HU, no ADC values measurable; Burgundy voxels=not ventilated, CT 
emphysema, no ADC values measurable. Clear=registration error. 
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2.2.7 Statistical Analysis 
Statistical tests were performed using SPSS Statistics V25.0 (SPSS Inc., Armonk, NY).  A 
Shapiro-Wilk test was used to determine the normality of the data. Kruskal-Wallis tests with 
post hoc Dunn-Bonferroni were used to determine differences between groups for mPRM 
voxel distributions. Spearman correlation coefficients with a Bonferroni correction were 
determined for mPRM voxel distributions, pulmonary function, and quality of life test 
measurements. Since each clinical measurement was correlated multiple times with every 
mPRM classification measurement, a Bonferroni correction of six was multiplied to the 
original p-values, and the adjusted p-values were compared for significance.  All results were 
considered statistically significant when the probability of making a Type I error was less than 
5% (p<.05). 
2.3 RESULTS 
2.3.1 Study Participants 
All participants were 48-87 years old (mean age: 69±9 years; mean age in men: 70±10 years; 
age range in men: 48-87 years; mean age in women: 68±8 years; age range in women: 52-83 
years). We generated mPRM measurements as shown in Figure 2-2 and 2-3 in 175 ex-smokers 
without (n=67, 68±10 years, 39 men) and with GOLD grade I (n=24, 74±7 years, 20 men), II 
(n=49, 69±8 years, 29 men), and III/IV (n=35, 68±9 years, 20 men) COPD.  The mean and 
standard deviation of ADC values within the never-smoker group was 0.26 ± 0.04 cm2/s, which 
was consistent with previous work,35 and was used to determine the abnormal ADC threshold. 
The flowchart in Figure 2-1 shows that for 263 total participants enrolled, 53 withdrew prior 
to the first visit, 10 participants had bronchiectasis, not COPD and 25 participants did not 
complete imaging (either MRI or CT), resulting in 175 participants who were evaluated. 
 
Table 2-1 provides demographic, pulmonary function test, imaging and quality of life 
measurements for all participants and by subgroup classified according to GOLD criteria 
which were different across subgroups (all p≤.05). Figure 2-4 shows representative 3He 
ventilation MRI as well as ADC and CT relative area of the lung <-950 HU (RA950) maps. 
Figure 2-4 also shows there was qualitatively worse or increased MRI ventilation 
heterogeneity, ADC, and RA950 voxels (in yellow) with increasing COPD severity.  
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Table 2-1: Participant Demographics 
Parameter 
Mean (±SD) 
ALL 
(n=175) 
Ex-smokers 
without 
COPD 
(n=67) 
GOLD I 
(n=24) 
GOLD II 
(n=49) 
GOLD 
III/IV 
(n=35) 
Age years 69 (9) 68 (10) 74 (7) 69 (8) 68 (9) 
Male n (%) 108 (62) 39 (58) 20 (83) 29 (59) 20 (57) 
BMI kg/m2 28 (5) 29 (4) 28 (4) 26 (4) 26 (5) 
Pack Years 40 (28) 28 (18) 48 (34) 46 (28) 53 (30) 
FEV1 %pred 77 (28) 98 (19) 95 (11) 64 (9) 35 (7) 
FVC %pred 91 (19) 92 (17) 109 (12) 92 (15) 71 (15) 
FEV1/FVC % 62 (18) 80 (6) 63 (5) 53 (9) 38 (8) 
TLC %pred 111 (18) 101 (14) 112 (12) 115 (18) 125 (17) 
RV/TLC %pred 121 (27) 107 (18) 107 (17) 125 (18) 161 (23) 
RAW %pred 170 (140)
* 115 (66) 122 (44) 175 (112) 314 (218)** 
DLCO %pred 65 (23)
* 79 (21) 69 (19) 57 (18)*** 42 (18)**** 
RA950 % 6 (9) 1 (1) 4 (4) 8 (9) 16 (11) 
VDP % 12 (10) 6 (4) 8 (5) 14 (8) 25 (9) 
ADC cm2/s 0.35 (.11) 0.26 (.03) 0.34 (.08) 0.39 (.10) 0.46 (.09) 
SGRQ Total 35 (22)‡ 25 (22)† 23 (16)⁂ 38 (15)*** 58 (13)**** 
6MWD m 393 (87)⸸ 405 (91)£ 420 (49) 399 (88)§ 340 (83)⁑ 
%pred, percent predicted; BMI, body mass index; FEV1, forced expiratory volume in 1 second; 
FVC, forced vital capacity; TLC, total lung capacity; RV, residual volume; RAW, airways 
resistance; DLCO, diffusing capacity of the lung for carbon monoxide; RA950, relative area of 
the lung < -950 Hounsfield units; VDP, ventilation defect percent; ADC, apparent diffusion 
coefficient; SGRQ, St. George’s Respiratory Questionnaire; 6MWD, six-minute walk distance; 
SD, standard deviation; GOLD, Global initiative for chronic Obstructive Lung Disease grade; 
COPD, chronic obstructive pulmonary disease. 
*n=173 **n=33 ***n=48 ****n=34 ‡n=165 †n=61 ⁂n=22 ⸸n=163 £n=65 §n=46 ⁑n=28 
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Figure 2-4. Representative Coronal MRI and CT by COPD Severity 
Ventilation is shown in aqua. Yellow highlights areas of the lung with CT attenuation < -950 
Hounsfield units on inspiratory CT 
Ex-smoker without COPD: 56-year-old man with a 41-pack-years smoking history and normal 
pulmonary function including FEV1=101%, FEV1/FVC=0.89; RV/TLC=106%, DLCO=79% 
(all % predicted) 
GOLD I: 87-year-old man with a 15-pack-years smoking history and modestly abnormal 
pulmonary function including FEV1=88%, FEV1/FVC=0.60; RV/TLC=95%; DLCO=59% (all 
%predicted) 
GOLD II: 77-year-old woman with a 112-pack-years smoking history and abnormal airflow, 
hyperinflation and diffusing capacity FEV1=66%, FEV1/FVC=0.51, RV/TLC=145%, 
DLCO=49% (all %predicted) 
GOLD III/IV: 76-year-old woman with a 30-pack-years smoking history and highly abnormal 
airflow, hyperinflation and highly abnormal diffusing capacity (FEV1=37%, FEV1/FVC=0.52, 
RV/TLC=139%, DLCO=19% (all %predicted)) 
FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; RV, residual volume; 
TLC, total lung capacity; DLCO, diffusing capacity of the lung for carbon monoxide; COPD, 
chronic obstructive pulmonary disease; RA950, relative area of the lung < -950 Hounsfield 
units; ADC, apparent diffusion coefficient. 
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2.3.2 mPRM Lung Fraction Measurements 
Figure 2-5 shows the resultant mPRM findings for all participants by lung fraction and 
representative centre-slice coronal mPRM maps for a representative ex-smoker and 
representative COPD participants.  Figure 2-5A shows there was a larger fraction of normal 
(green) mPRM voxels in ex-smokers (all p≤.001) and a smaller fraction of abnormal (yellow, 
orange, red and burgundy) mPRM voxels compared with all subgroups of COPD participants.  
Ex-smokers without COPD also reported a smaller fraction of unventilated, normal CT voxels 
compared to ex-smokers with GOLD II and III/IV COPD (all p<.001).  mPRM revealed two 
novel mPRM voxel types (yellow and red) that were both present in “normal” ex-smokers and 
which reflect mild emphysema or hyperinflation and airways disease respectively. Figure 2-
5B also shows there was a greater fraction of abnormal mPRM voxels as COPD severity 
increased.  
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Figure 2-5. mPRM Lung Fraction Measurements and Increasing COPD Severity 
A. mPRM voxel category by lung fraction for all ex-smokers without COPD (n=67), 
GOLD grade I (n=24), II (n=49) and III/IV (n=35). In ex-smokers with no spirometric 
evidence of COPD there was a greater fraction of normal voxels and smaller fraction 
of abnormal voxels than in subgroups of COPD. As COPD grade increases, there is a 
decrease in normal voxels, and an increase in abnormal voxels. 
B. Representative mPRM voxel maps for an ex-smoker without COPD (79-year-old, 32 
pack years) (mainly green (normal) and yellow (ventilated, CT ≥ -950 HU, abnormal 
ADC) voxels) and participants with GOLD grade I (71-year-old, 66 pack years) 
(mainly yellow, orange (ventilated, CT emphysema, abnormal ADC) and red (not 
ventilated, CT ≥ -950 HU) voxels), GOLD grade II (86-year-old, 50 pack years) 
(similar to GOLD I except with a greater amount of orange and red voxels) and GOLD 
grade III/IV (68-year-old, 93 pack years) (similar to GOLD II except with greater 
amounts of burgundy (not ventilated, CT emphysema) voxels). 
* indicates p≤.001 compared to ex-smokers without COPD 
** indicates p<.01 compared to GOLD I 
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2.3.3 mPRM Relationships with Pulmonary Measurements 
Table 2-2 shows Spearman correlation coefficients for mPRM lung fraction measurements 
with FEV1 %pred, the ratio of FEV1 to forced vital capacity (FVC), DLCO, the St. George’s 
Respiratory Questionnaire (SGRQ) total score, and six-minute walk distance in ex-smokers 
with and without COPD.  In all participants, normal mPRM lung fraction measurements (green 
voxels in Figure 2-3 and 2-5) were correlated with FEV1 %pred (r = 0.65, p<.001), FEV1/FVC 
(r = 0.81, p<.001), DLCO (r = 0.75, p<.001), and SGRQ (r = -0.48, p<.001).  mPRM ventilated, 
normal CT and abnormal ADC (yellow) lung fraction measurements were correlated with 
FEV1 %pred (r = -0.42, p<.001), FEV1/FVC (r = -0.60, p<.001), DLCO (r = -0.60, p<.001), and 
SGRQ (r = 0.33, p<.001).   Table 2-2 also shows that mPRM ventilated, CT emphysema and 
abnormal ADC (orange) lung fraction measurements were correlated with FEV1 %pred (r = -
0.64, p<.001), FEV1/FVC (r = -0.83, p<.001), DLCO (r = -0.66, p<.001), and SGRQ (r = 0.45, 
p<.001).  Unventilated with normal CT (red in Figure 2-3 and 2-5) mPRM lung fraction 
measurements were correlated with FEV1 %pred (r = -0.65, p<.001), FEV1/FVC (r = -0.70, 
p<.001), DLCO (r = -0.53, p<.001), and SGRQ (r = 0.45, p<.001) whereas unventilated, CT 
emphysema (dark burgundy) lung fraction measurements were correlated with FEV1 %pred (r 
= -0.72, p<.001), FEV1/FVC (r = -0.86, p<.001), DLCO (r = -0.63, p<.001), and SGRQ (r = 
0.46, p<.001).  Table 2-2 also shows that all mPRM lung fraction measurements except for 
ventilated, CT ≥ -950 HU, abnormal ADC voxels were correlated with six-minute walk 
distance. Figure 2-6 to 2-10 show univariate regressions for mPRM lung fraction 
measurements and clinical measures while Table 2-3 provides Spearman correlation 
coefficients for all disease severity subgroups. 
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Table 2-2: Spearman Correlation Coefficients for mPRM Voxel Classes as a Fraction of Total 
Lung 
Spearman 
correlation 
coefficient  
R (p) 
Normal 
(% of lung)  
Ventilated+ 
CT ≥ -950 HU+ 
Abnormal ADC 
(% of lung)  
Ventilated+ 
CT Emphysema+ 
Abnormal ADC 
(% of lung) 
Not Ventilated+ 
CT ≥ -950 HU+ 
No ADC 
(% of  lung) 
Not Ventilated+ 
CT Emphysema+ 
No ADC 
(% of lung) 
All study participants  (n=175)     
FEV1%pred .65 (<.001) -.42 (<.001) -.64 (<.001) -.65 (<.001) -.72 (<.001) 
FEV1/FVC % .81 (<.001) -.60 (<.001) -.83 (<.001) -.70 (<.001) -.86 (<.001) 
DLCO%pred* .75 (<.001) -.60 (<.001) -.66 (<.001) -.53 (<.001) -.63 (<.001) 
SGRQ** -.48 (<.001) .33 (<.001) .45 (<.001) .45 (<.001) .46 (<.001) 
6MWD*** .28 (.002) -.19 (.08) -.27 (.003) -.29 (.001) -.29 (.001) 
P values adjusted using Bonferroni correction of six to account for multiple comparisons for multi-
parametric response map voxel classes. Significant correlations are bold. ADC, apparent diffusion 
coefficient; HU, Hounsfield unit; FEV1, forced expiratory volume in 1 second; FVC, forced vital 
capacity; DLCO, diffusing capacity of the lung for carbon monoxide; SGRQ, St. George’s Respiratory 
Questionnaire total score; 6MWD, six-minute walk distance; mPRM, multi-parametric response map. 
*n=173 **n=165 ***n=163 
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Figure 2-6: Spearman Correlations for Normal mPRM Voxel Class and Clinical Measures 
%pred, percent predicted; FEV1, forced expiratory volume in one second; FVC, forced vital 
capacity; DLCO, diffusing capacity of the lung for carbon monoxide, SGRQ, St. George’s 
Respiratory Questionnaire; mPRM, multi-parametric response map.  
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Figure 2-7: Spearman Correlations for Ventilated, CT Normal with Abnormal ADC mPRM 
Voxel Class and Clinical Measures 
%pred, percent predicted; FEV1, forced expiratory volume in one second; FVC, forced vital 
capacity; DLCO, diffusing capacity of the lung for carbon monoxide, SGRQ, St. George’s 
Respiratory Questionnaire; mPRM, multi-parametric response map; ADC, apparent diffusion 
coefficient.  
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Figure 2-8: Spearman Correlations for Ventilated, CT Emphysema and Abnormal ADC 
mPRM Voxel Class and Clinical Measures 
%pred, percent predicted; FEV1, forced expiratory volume in one second; FVC, forced vital 
capacity; DLCO, diffusing capacity of the lung for carbon monoxide, SGRQ, St. George’s 
Respiratory Questionnaire; mPRM, multi-parametric response map; ADC, apparent diffusion 
coefficient.  
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Figure 2-9: Spearman Correlations for Unventilated, CT Normal mPRM Voxel Class and 
Clinical Measures 
%pred, percent predicted; FEV1, forced expiratory volume in one second; FVC, forced vital 
capacity; DLCO, diffusing capacity of the lung for carbon monoxide, SGRQ, St. George’s 
Respiratory Questionnaire; mPRM, multi-parametric response map; ADC, apparent diffusion 
coefficient.  
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Figure 2-10: Spearman Correlations for Unventilated, CT Emphysema mPRM Voxel Class 
and Clinical Measures 
%pred, percent predicted; FEV1, forced expiratory volume in one second; FVC, forced vital 
capacity; DLCO, diffusing capacity of the lung for carbon monoxide, SGRQ, St. George’s 
Respiratory Questionnaire; mPRM, multi-parametric response map; ADC, apparent diffusion 
coefficient.  
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Table 2-3: Spearman Correlation Coefficients for mPRM Voxel Classes as a Fraction of Total 
Lung 
Spearman 
R (p) 
Normal 
(% of lung)  
Ventilated+ 
CT ≥ -950 HU+ 
Abnormal ADC 
(% of lung)  
Ventilated+ 
CT Emphysema+ 
Abnormal ADC 
(% of lung) 
Not Ventilated+ 
CT ≥ -950 HU+ 
No ADC 
(% of  lung) 
Not Ventilated+  
CT Emphysema+ 
No ADC 
(% of lung) 
All (n=175)     
FEV1%pred .65 (<.001) -.42 (<.001) -.64 (<.001) -.65 (<.001) -.72 (<.001) 
FEV1/FVC % .81 (<.001) -.60 (<.001) -.83 (<.001) -.70 (<.001) -.86 (<.001) 
DLCO%pred
* .75 (<.001) -.60 (<.001) -.66 (<.001) -.53 (<.001) -.63 (<.001) 
SGRQ** -.48 (<.001) .33 (<.001) .45 (<.001) .45 (<.001) .46 (<.001) 
6MWD*** .28 (.002) -.19 (.08) -.27 (.003) -.29 (.001) -.29 (.001) 
Ex-smokers (n=67)     
FEV1%pred -.14 (>.99) .10 (>.99) .12 (>.99) .06 (>.99) -.05 (>.99) 
FEV1/FVC % .22 (.08) -.20 (.65) -.27 (.18) -.16 (>.99) -.33 (.04) 
DLCO%pred .40 (.01) -.41 (.01) -.06 (>.99) -.27 (.18) -.09 (>.99) 
SGRQ**** -.30 (.12) .32 (.08) .24 (.40) .06 (>.99) .18 (>.99) 
6MWD† .33 (.04) -.35 (.02) -.30 (.09) -.20 (.64) -.31 (.08) 
GOLD I (n=24)     
FEV1%pred .15 (>.99) -.15 (>.99) -.14 (>.99) -.14 (>.99) -.15 (>.99) 
FEV1/FVC % .40 (.31) -.38 (.40) -.46 (.13) -.03 (>.99) -.27 (>.99) 
DLCO%pred .70 (.001) -.62 (.01) -.68 (.001) -.39 (.37) -.46 (.14) 
SGRQ⁑ -.25 (>.99) .25 (>.99) .17 (>.99) .33 (.82) .33 (.84) 
6MWD -.01 (>.99) .09 (>.99) -.09 (>.99) -.40 (.31) -.36 (.52) 
GOLD II (n=49)     
FEV1%pred .18 (>.99) -.02 (>.99) -.18 (>.99) -.24 (.57) -.37 (.05) 
FEV1/FVC % .47 (.01) -.15 (>.99) -.55 (<.001) -.36 (.07) -.65 (<.001) 
DLCO%pred§ .67 (<.001) -.54 (<.001) -.63 (<.001) .03 (>.99) -.44 (.01) 
SGRQ§ -.11 (>.99) .22 (.80) 0 (>.99) .03 (>.99) -.08 (>.99) 
6MWD⁋ .05 (>.99) -.12 (>.99) -.02 (>.99) -.03 (>.99) 0 (>.99) 
GOLD III/IV (n=35)     
FEV1%pred -.08 (>.99) .41 (.08) -.31 (.41) .04 (>.99) -.34 (.28) 
FEV1/FVC % .51 (.01) .34 (.27) -.62 (<.001) -.12 (>.99) -.63 (<.001) 
DLCO%pred‡ .73 (<.001) .14 (>.99) -.71 (<.001) .03 (>.99) -.58 (.002) 
SGRQ‡ -.17 (>.99) -.14 (>.99) .07 (>.99) .14 (>.99) .22 (>.99) 
6MWD⸹ .09 (>.99) .28 (.94) -.14 (>.99) -.20 (>.99) -.23 (>.99) 
P values adjusted using Bonferroni correction of six to account for multiple comparisons for multi-
parametric response map voxel classes. Significant correlations are bold. ADC, apparent diffusion 
coefficient; HU, Hounsfield unit; FEV1, forced expiratory volume in 1 second; FVC, forced vital 
capacity; DLCO, diffusing capacity of the lung for carbon monoxide; SGRQ, St. George’s Respiratory 
Questionnaire total score; 6MWD, six-minute walk distance; mPRM, multi-parametric response map. 
*n=173 **n=165 ***n=163 ****n=61 †n=65 ⁑n=22 §n=48 ⁂n=46 ‡n=34 ⸸n=28 
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2.3.4 mPRM Phenotypes in Ex-smokers without COPD 
Figure 2-11 shows mPRM maps for four representative ex-smokers with normal spirometry 
and CT. These maps highlight the heterogeneity observed in ex-smokers and the regional 
distribution of mPRM voxels including green (normal ventilation, CT and ADC), yellow 
(normal ventilation and CT, abnormal ADC) and red (not ventilated, normal CT) voxels. For 
example, Figure 2-11A shows the resultant green (or normal) mPRM map for a 51-year-old 
man with 32-pack-year history, normal spirometry (FEV1=75%pred, FEV1/FVC=0.77) and 
normal DLCO (95%pred). In contrast, in Figure 2-11B, there is a mixture of green (normal) and 
yellow (ventilated, CT ≥ -950 HU, abnormal ADC) mPRM voxels in a 76-year-old man with 
24-pack-years smoking history, normal spirometry (FEV1=115%pred, FEV1/FVC=0.72) and 
abnormal DLCO (59%pred). Figure 2-11C provides another mPRM map for a participant with 
similar pulmonary function measurements (80-year-old woman, 27-pack-year history, normal 
spirometry (FEV1=124%pred, FEV1/FVC=0.71), abnormal DLCO (49%pred)) which is 
comprised of mainly yellow (ventilated, CT ≥ -950 HU, abnormal ADC) mPRM voxels. 
Finally, Figure 2-11D shows the mPRM map for a 72-year-old man, with 20-pack-years 
smoking history, normal spirometry (FEV1=122%pred, FEV1/FVC=0.80) and DLCO 
(73%pred) which consists of a mixture of green (normal) mPRM voxels throughout and red 
(not ventilated, CT ≥ -950 HU) voxels in wedge-shaped peripheral (subsegmental) lung 
regions.   
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Figure 2-11. mPRM Maps in Representative Ex-smokers without COPD 
A. Mainly green (normal) voxels in a 51-year-old man, 32-pack-years, FEV1=75%, 
FEV1/FVC=0.77, DLCO=95% 
B. Mixture of green (normal) and yellow (ventilated, CT ≥ -950 HU, abnormal ADC) voxels 
in a 76-year-old man, 24-pack-years, FEV1=115%, FEV1/FVC=0.72, DLCO=59% 
C. Mainly yellow (ventilated, CT ≥ -950 HU, abnormal ADC) voxels in a 80-year-old woman, 
27-pack-years, FEV1=124%, FEV1/FVC=0.71, DLCO=49% 
D. Mixture of green (normal), yellow (ventilated, CT ≥ -950 HU, abnormal ADC) and red (not 
ventilated, CT ≥ -950 HU) voxels in a 72-year-old man, 20-pack-years, FEV1=122%, 
FEV1/FVC=0.80, DLCO=73%  
(all %predicted) 
 
 
2.4 DISCUSSION 
Previous work has shown that hyperpolarized gas MRI and CT provide complementary disease 
information in COPD, but this information has not been combined into a single image.  In this 
study, we generated mPRM measurements, combining CT and MRI, in 175 ex-smokers 
including 108 participants with and 67 participants without COPD. We observed: 1) 
significantly different mPRM lung fraction measurements with increasing disease severity, 2) 
significant associations for mPRM lung fraction measurements with pulmonary function and 
quality of life (all p<.001), and 3) two mPRM voxel types that were suggestive of disease 
transition/progression in ex-smokers with normal spirometry and CT, neither of which were 
detected using CT or MRI alone. 
 
Lung fraction measurements using mPRM were significantly different with increasing COPD 
severity which is not surprising in light of previous single modality CT and MRI studies in 
COPD.4,21,24,36 These previous studies also showed that as COPD severity increases, there is a 
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decrease in total airway count and terminal bronchioles.24,36 With increasing COPD severity, 
mPRM measurements also transition from mainly normal voxels to hyper-inflated or mild 
emphysema voxels, to ventilation abnormalities and then advanced emphysema with 
ventilation abnormalities. 
 
These mPRM lung fraction measurements were also correlated with pulmonary function, 
quality of life and exercise capacity measurements. The relationship of mPRM phenotypes 
with DLCO measurements appears to transition from potential sub-clinical emphysema in ex-
smokers with normal spirometry and CT to progressively more severe emphysema in COPD. 
These results are consistent with previous findings of the strong relationship between DLCO 
and measures of emphysema.2,3,22 
 
By identifying abnormal lung regions using mPRM maps, there is the potential to provide 
insight into the transition from normal to diseased COPD states and this hypothesis requires 
testing in a prospective longitudinal study.  The heterogeneity of mPRM maps in at-risk ex-
smokers shows the presence of abnormal lung regions that are not obvious on CT or MRI 
alone.  Voxels with normal CT and ventilation but abnormal ADC can be interpreted in the 
context of previous work that revealed MRI evidence of subclinical airspace enlargement (due 
to emphysema or alveolar distension) in a small group of ex-smokers without CT RA950 
measurements consistent with emphysema.22  Regions of elevated ADC may indicate regions 
of subclinical emphysema, possible alveolar distension or gas-trapping and are consistent with 
previous findings.21,22  While not visible on CT or reflected using spirometry, these 
microstructural changes may also be an indicator of early terminal airspace destruction. 
 
Another key finding, in an apparently normal ex-smoker, is regions of the lung that have 
normal CT voxels but no gas distribution. These regions are consistent with subsegmental 
small airways disease.  In COPD, the narrowing or destruction of the small airways is thought 
to precede the development of emphysema,36 but these affected small airways cannot be 
detected with spirometry and are CT invisible.14,37  CT PRM has also provided a way to 
regionally identify gas-trapping based on voxels that are normal on inspiration CT but 
abnormal (<856HU) on expiration CT,4,14 and has been validated as an imaging measurement 
of small airways disease in very severe COPD.38  Multi-modality mPRM maps unite structural 
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and functional abnormalities in a way that resembles CT PRM measurements of emphysema 
and small airways disease, and may provide another way to highlight the transition phases in 
COPD. Further evaluation of unventilated, normal CT voxels is required with CT airway and 
PRM measurements to clarify the pathophysiology responsible for these findings. 
 
We expected to observe overlap of structure-function imaging findings in participants with 
COPD. In other words, the mPRM findings in GOLD grade I through IV are in keeping with 
our understanding of COPD pathophysiology and the finding of  increasingly abnormal tissue 
and airway structure-function in participants with more advanced or severe COPD. However, 
we did not expect, based on previous findings to observe mPRM evidence of airways disease 
(not ventilated, normal CT) and mild emphysema (ventilated, normal CT, abnormal ADC) in 
ex-smokers with otherwise normal CT and spirometry values. These two novel findings in a 
highly heterogeneous convenience sample of ex-smokers without airflow obstruction 
challenge our understanding of normal pulmonary function test results in ex-smokers who 
currently are not considered to have, nor are treated for COPD. 
 
We acknowledge several study limitations including the fact that MRI-CT co-registration 
errors will influence voxel classification. Importantly, CT and MRI were acquired at the same 
lung volume, assisting with image registration accuracy (Supplement). ADC images have 
twice the slice thickness compared to the ventilation images, which often makes resampling 
complex.  We also used a fixed threshold for CT emphysema3 and an experimentally derived 
fixed ADC threshold based on assumptions about age-matched never-smoker ADC values.33 
Other factors35,39 may influence ADC values in participants with relatively healthy lungs and 
therefore the ADC threshold we used may not represent terminal airspace enlargement or 
emphysema but perhaps airspace distention. We acquired CT images at functional residual 
capacity+1L instead of full inspiration, validated for CT emphysema measurements (-
950HU).3  For the participants in our study, and based on plethysmographic data, functional 
residual capacity+1L = 80-90% of total lung capacity, especially when lying supine in the 
scanner.  This means that the estimates of CT emphysema here should be considered as 
fractionally lower than estimates for patients at full inflation, but this difference is unlikely to 
be clinically relevant.34 Nevertheless, the emphysema estimates in our participants are similar 
to those in other published studies such as MESA,9 CanCOLD,40 SPIROMICS5 and 
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COPDGene.41  Another limitation of this study was the lack of a control group of age-matched 
never-smokers which would help provide a better understanding of the physiological relevance 
of the mPRM values. Longitudinal data on the lack of progression (or the progression of) these 
two new imaging phenotypes of COPD remains to be investigated. 
 
In conclusion, we developed a multi-modality image processing pipeline to generate 
pulmonary mPRM measurements that were related to pulmonary function tests and quality of 
life and revealed phenotypes in at-risk ex-smokers not detected using CT or MRI alone. To our 
knowledge, this is the first multi-parametric analysis of thoracic CT and MRI in patients with 
COPD and at-risk ex-smokers.    
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2.6 SUPPLEMENT 
2.6.1 Materials and Methods 
2.6.1.1 Pulmonary Function and Quality of Life Tests 
Participants were seated in a body plethysmograph (MedGraphics Elite Series, MGC 
Diagnostic Corporation, St. Paul, MN) and coached through the breathing maneuvers for 
spirometry, plethysmography, and diffusing capacity according to the American Thoracic 
Society and European Respiratory Society guidelines. Afterwards, the participants filled out 
the St. George’s Respiratory Questionnaire with staff nearby to answer any questions they may 
have about the questionnaire. Finally, the participants performed a six-minute walk test at a 
brisk walking pace that was comfortable to them. Before and after the test, participant’s heart 
rate and SaO2 were recorded. 
2.6.1.2 MRI Acquisition 
All MR acquisition parameters have been described elsewhere;1 but briefly, anatomical proton 
(1H) was acquired using a fast-spoiled gradient-recalled echo (FGRE) sequence with a partial 
echo: total acquisition time = 16 seconds, repetition time [TR] = 4.7 ms, echo time [TE] = 1.2 
ms, flip angle = 30°, field of view [FOV] = 40x40 cm; matrix =128x80 (zero padded to 
128x128), bandwidth = 24.4 kHz, one excitation, 15-17 slices, slice thickness = 15 mm, 0 gap. 
Hyperpolarized 3He static ventilation was acquired using an FGRE sequence with a partial 
echo: total acquisition time = 14 seconds, TR = 4.3 ms, TE = 1.4 ms, flip angle = 7°, FOV = 
40x40 cm, bandwidth = 48.8 kHz, matrix = 128x80 (zero padded to 128x128), 15-17 slices, 
slice thickness = 15 mm, 0 gap. Diffusion-weighted 3He MRI was performed using an FGRE 
sequence with total acquisition time = 14 seconds, TR = 7.6 ms, TE = 3.7 ms, flip angle = 8°, 
FOV = 40x40 cm, matrix = 128x128, 7-9 slices, slice thickness = 30 mm, 0 gap, with and 
without additional diffusion sensitization with b = 1.6 s/cm2 (gradient amplitude (G) = 1.94 
G/cm, rise and fall time = 0.5 ms, gradient duration = 0.46 ms, diffusion time = 1.46 ms). 
2.6.1.3 CT Imaging 
CT acquisition parameters have been described elsewhere.1  Briefly, a non-contrast low-dose 
single spiral acquisition during a breath-hold was used: detector configuration = 64x0.625 mm, 
peak voltage = 120 kVp, effective current = 100 mA, rotation time = 500 ms, pitch = 1.0, slice 
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thickness = 1.25 mm, number of slices = 200-250, matrix = 512x512. The CT was acquired 
axially, and reconstructed to a slice interval of 1.25 mm using a standard convolution kernel. 
Total effective dose was estimated as 1.8 mSv using the ImPACT CT patient dosimetry 
calculator (based on Health Protection Agency [UK] NRBP-SR250). 
2.6.1.4 MR Image Analysis 
3He static ventilation images were segmented using a k-means clustering algorithm to divide 
the image into five clusters with the first cluster being ventilation defect, and the fifth cluster 
being regions of hyper-intense signal. The thoracic cavity volume was segmented for the 1H 
images using a seeded region growing algorithm as previously described2.  Diffusion-weighted 
images were segmented by applying a 2-D Hanning window to the k-space data of the non-
diffusion-weighted image to improve the signal-to-noise ratio between the lungs and the 
background. An intensity-based threshold was applied to the non-diffusion-weighted image to 
generate a mask of ventilated lung and this mask was then applied to both the diffusion-
weighted and non-diffusion-weighted images to isolate the ventilated lung.  These segmented 
images were processed to generate lung apparent diffusion coefficient (ADC) maps on a voxel-
wise basis using equation 1: 
𝐴𝐷𝐶 =
1
𝑏
ln (
𝑆0
𝑆
)         (1) 
where S0 is the signal intensity of the non-diffusion-weighted image, S is the signal intensity 
of the diffusion-weighted image, and b is the diffusion gradient (b = 1.6 s/cm2). 
2.6.1.5 Image Registration 
The image registration pipeline has been described elsewhere.3 Briefly, the volume matched 
CT and ADC images were resized to match the proton image voxel dimensions using nearest 
neighbor interpolation to preserve the original image information. Volume matched 3He and 
1H images were registered using a landmark-based affine registration approach as previously 
described2. The CT and 1H MRI were non-rigidly registered using a symmetric modality 
independent neighborhood descriptor (MIND) method.4 Since the 3He static ventilation and 
ADC images are both determined by lung ventilation, a rigid registration method was used to 
co-register these images. The Dice Similarity Coefficients for the 175 participants were 95±1% 
for the CT to 1H registration and 84±5% for 3He ADC to 3He ventilation registration. 
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CHAPTER 3 
 
3 CONCLUSIONS AND FUTURE DIRECTIONS 
In this final chapter, a summary and overview is provided for the important findings and 
conclusions presented in Chapter 2. Limitations specific to this study are provided along with 
possible solutions. Finally, the chapter concludes by discussing future directions for the 
methods developed and discussed here. 
3.1 Overview and Research Objectives 
Hyperpolarized gas MRI and CT have been used to provide regional information about the 
lung and to supplement spirometry in the phenotyping of COPD. Typically, only one imaging 
modality is used, looking at either CT structure or MRI structure/function. The overarching 
objective of this thesis was to develop and apply a multi-modality image processing pipeline 
to generate combined CT and MRI measurements. We postulated that combined CT and MRI 
measurements would reveal phenotypes of COPD that were undetected using MRI or CT alone. 
The specific objectives were first to develop a multi-modality image processing pipeline to 
generate multi-parametric response maps from CT and MRI measurements, and second to 
apply this pipeline to a large cohort of COPD patients. 
3.2 Summary and Conclusions 
In Chapter 2, we developed an image processing pipeline to generate multi-parametric 
response maps from co-registered CT, 3He MRI ventilation and ADC images. We applied this 
pipeline to a large cohort of ex-smokers with and without COPD and investigated the 
relationship between our multi-parametric measures and disease severity, pulmonary function, 
quality of life, and exercise capacity. 175 ex-smokers (108 with and 67 without COPD) were 
evaluated. Multi-parametric measurements became increasingly more abnormal with disease 
severity, and correlated with pulmonary function, exercise capacity, and quality of life 
measurements. These results indicate the potential of this multi-parametric approach to detect 
new phenotypes of COPD as well as clarify the relationship of these measures with disease 
severity. 
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3.3 Limitations 
Although Chapter 2 presented positive results for the first MRI-CT multi-parametric analysis 
of COPD, there are a number of limitations that need to be addressed. The first major limitation 
is the fact that MRI-CT co-registration errors will influence voxel classification. To assist with 
image registration accuracy, CT and MRI were acquired at the same lung volume. 
Additionally, the larger slice thickness of the ADC images compared to the ventilation images 
made resampling complex due to signal averaging and partial volume effects. Next, the fixed 
thresholds we used were based on an established cut-off for CT emphysema1 as well as an 
experimentally derived fixed ADC threshold based on assumptions about age-matched never-
smoker ADC values.2 Other factors such as gravity induced tissue compression,3-6 age7 and 
airspace distention due to gas-trapping8,9 may influence ADC values in participants with 
relatively healthy lungs; therefore, the ADC threshold we used may not represent terminal 
airspace enlargement or emphysema. As mentioned above, we acquired CT images at 
functional residual capacity+1L instead of full inspiration to help with image registration, but 
this volume may influence the CT emphysema measurements calculated from the validated 
threshold (-950HU)1 used.  For the participants in our study, and based on plethysmographic 
data, functional residual capacity+1L = 80-90% of total lung capacity, especially when lying 
supine in the scanner.  This means that the estimates of CT emphysema here should be 
considered as fractionally lower than estimates for patients at full inflation, but this difference 
is unlikely to be clinically relevant.10 To further address any differences, emphysema 
measurements from other published studies such as MESA,11 CanCOLD,12 SPIROMICS13 and 
COPDGene14 were similar to those measured in our cohort. The last limitation was the lack of 
a control group of age-matched never-smokers which would help provide a better 
understanding of the physiological relevance of the mPRM values, and  any longitudinal data 
on the lack of progression (or the progression of) these new imaging phenotypes of COPD. 
 
A general limitation to the method presented in this thesis is the availability of the specific 
imaging data necessary to generate the multi-parametric response maps. The limited 
availability of hyperpolarized gas MRI due to cost and specialized hardware, the differences 
in diffusivity between 129Xe and 3He as well as the need for same-day CT acquisitions reduces 
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the generalizability of this method to other sites. Application of the multi-parametric method 
to other imaging modalities may be possible to overcome this limitation.  
 
3.4 Future Directions 
3.4.1 mPRM in Normal versus Abnormal DLCO 
As seen from the results of our study, multi-parametric measures related to possible micro-
structure abnormalities are present in ex-smokers without COPD and are related to diffusing 
capacity. Previous work3,15 observed that impairment in diffusing capacity was related to 
reduced exercise capacity and worse quality of life independent of CT evidence of emphysema, 
and suggested that diffusing capacity may be sensitive to sub-clinical emphysema within 
COPD.  Using the ability of this mPRM analysis to visualize possible transition phases of 
COPD, we hypothesize that multi-parametric measures related to sub-clinical emphysema will 
be related to exercise capacity and quality of life in ex-smokers with abnormal diffusing 
capacity. This investigation may elucidate early transitions of the disease and possibly identify 
new targets for treatment.  
3.4.2 Longitudinal Study of mPRM in TINCan Cohort 
As mentioned in the limitations, future work must be done to apply the method developed in 
Chapter 2 to longitudinal data. From our cross-sectional analysis, we can infer a progression 
of mPRM measurements with increasing disease severity. By investigating these 
measurements over time, information would be provided about the progression of COPD in 
individuals and its corresponding visualization on mPRM. Previous work has observed 
significant changes in CT and MR imaging measurements over time in COPD.16,17 Therefore, 
it is hypothesized that the method presented in this thesis will also provide similar results. 
3.4.3 Multi-parametric Measures in Other Modalities 
Finally, our method relies on the uniqueness of the TINCan imaging data to generate our multi-
parametric measures. Application to other imaging modalities may provide a more clinically 
feasible implementation of our methodology. Advances in xenon enhanced dual energy CT, 
UTE and FDMRI allow for the unique application of the multi-parametric methodology to be 
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investigated in COPD.  First, the simultaneous acquisitions in xenon enhanced dual energy CT 
allows for inherent co-registration between the structure and ventilation images and reduces 
the effects of registration errors on the multi-parametric response maps. By using this imaging 
technique, additional information from airway measurements can be integrated into the 
analysis and underestimation of emphysema can be reduced by acquiring at total lung capacity. 
Next, UTE MRI would provide a radiation free implementation of this method in sites setup 
for hyperpolarized gas MRI. Current UTE acquisitions provide similar structural information 
to low-dose CT,18 and since our method used low-dose CT to provide the structural 
measurements, UTE may provide a suitable replacement. Additionally, using UTE would 
provide similar spatial resolution as hyperpolarized gas MRI thereby reducing any errors 
generated during the resampling process. Finally, FDMRI’s capability to generate ventilation 
images combined with UTE MRI’s structural images allows for an entire 1H based multi-
parametric response map. Such an application would take advantage of more widely available 
1H MRI and possibly provide a clinical implementation of the multi-parametric response map 
method. 
 
3.5 Significance and Impact 
Many studies17,19-21 have used CT and hyperpolarized gas MRI to provided measure of lung 
structure and function for phenotyping the underlying pathophysiology of COPD. These 
studies have focused on using only one modality but not a combination of the two. By 
combining information from both imaging modalities, the method outlined in this thesis 
provided an imaging technique to visualize progression/transition phases in COPD and may 
be used to possibly identify new targets for treatment and disease monitoring. 
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APPENDICES 
 
Appendix A - Development and Evaluation of Pulmonary Imaging Multi-Parametric 
Response Maps for Deep Phenotyping of Chronic Obstructive Pulmonary Disease 
 
In Appendix A we developed a novel image processing pipeline to generate combined CT and 
MRI Multi-Parametric Response Maps and evaluated these maps in a small cohort of ex-
smokers with and without COPD. 
 
The contents of this chapter have been previously published in SPIE Proceedings Volume 
10953, Medical Imaging 2019: Biomedical Applications in Molecular, Structural, and 
Functional Imaging; 109530J (2019) and permission to reproduce the article was granted by 
SPIE and is provided in Appendix C. 
Jonathan L. MacNeil, Dante P. I. Capaldi, Rachel L. Eddy, Andrew Westcott, Alexander M. 
Matheson, Andrea L. Barker, Cathy Ong-Ly, David G. McCormack M.D., and Grace Parraga 
"Development and evaluation of pulmonary imaging multi-parametric response maps for deep 
phenotyping of chronic obstructive pulmonary disease", Proc. SPIE 10953, Medical Imaging 
2019: Biomedical Applications in Molecular, Structural, and Functional Imaging, 109530J 
(15 March 2019); https://doi.org/10.1117/12.2512849 
 
INTRODUCTION 
Thoracic x-ray computed tomography (CT) has provided invaluable information about lung 
structure and function including patients with chronic obstructive pulmonary disease (COPD). 
A number of key cohort studies including ECLIPSE,1 COPDgene,2 SPIROMICS3 and 
CanCOLD4 have identified unique phenotypes related to airways disease and emphysema as 
well as bronchiectasis and gas-trapping. In addition to CT biomarkers of lung disease, 
hyperpolarized gas magnetic resonance imaging (MRI) has provided insight into asthma, 
COPD, and cystic fibrosis via ventilation5-8 and lung tissue microstructure9-11 measurements.  
Using lung CT and MRI measurements, COPD disease severity and risk of poor outcomes can 
be predicted. A recent approach12 used CT parametric response map (PRM) of voxel-wise CT 
inspiration and expiration images to monitor COPD progression in patients. Previous studies 
have used PRM to quantify changes in lung structure with increasing COPD severity,13 
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survival post-lung transplant,14 and survival/therapy efficacy in brain, neck, bone, and breast 
cancer treatment.15-18 Recently, PRM approaches have been extended to include a multi-
modality imaging methods towards the generation of multi-parametric response maps 
(mPRM).19 This mPRM approach was applied to MRI measurements of glioblastoma in 
patients which significantly predicted patient survival when PRM methods did not. 
In the TINCan cohort study,20 spatial correlations between hyperpolarized gas MRI static 
ventilation and CT measurements of healthy tissue, emphysema, and gas-trapping were 
shown.21 In addition, hyperpolarized gas MRI apparent diffusion coefficients (ADC) have also 
been validated histologically as biomarkers of emphysema.22,23 Unfortunately, multi-
parametric response maps with thoracic CT and MRI information have not been generated or 
tested in COPD patients, in whom it is difficult to predict disease worsening. Therefore, the 
purpose of this work was to create a pipeline to generate multi-parametric response maps, and 
to evaluate these maps to provide unique phenotypes of chronic obstructive pulmonary disease 
(COPD). 
 
MATERIALS AND METHODS 
 
Image Segmentation 
Figure 1 outlines the segmentation pipeline. Briefly, 1H/ 3He MR images were segmented by a 
single observer (D.P.I.C. with 3 years of experience) as previously described.24 The thoracic 
cavity was segmented from the 1H images using a seeded region-growing algorithm, and the 
3He ventilation was segmented using k-means clustering to classify the voxels into five 
categories (signal void to hyper-intense signal) to create a ventilation cluster map. The CT 
images were segmented by a single observer (D.P.I.C. with 2 years of experience) using 
Pulmonary Workstation 2.0 (VIDA Diagnostics, Coralville, IA, USA) to generate a lung mask 
to be applied to the CT images. 
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Figure 1: Segmentation Pipeline 
 
K-means Clustering 
3He MR images were segmented using k-means clustering.24 Four clusters were chosen to 
define signal void, hypointense signal, normal signal, and hyperintense signal. The initial 
cluster centroids were chosen by equally dividing the full pixel range (0-255) into four groups 
and choosing the interval center of each cluster as the centroid. The voxels were initially 
labelled by the nearest centroid (1). 
𝐶𝑖 ∶= arg min
𝑗
‖𝑥𝑖 − 𝜇𝑗‖
2
        (1) 
Ci is the cluster label, xi is the pixel intensity, and µj is the mean pixel intensity of the cluster. 
Once the labelling step was completed, a new centroid (2) was calculated as the mean pixel 
intensity of all the pixels within that cluster. 
µ𝑗 =  
∑ {𝑐𝑖=𝑗}𝑥𝑖𝑚𝑖=1
∑ {𝑐𝑖=𝑗}𝑚𝑖=1
, 𝑓𝑜𝑟 1 ≤ 𝑗 ≤ 𝑘     (2) 
where k is the total number of clusters wanted, j is the index of the current cluster, and m is 
total number of voxels within that cluster. This assignment step and centroid updating step 
were repeated until the algorithm converged. After the clustering algorithm converged, k-
means clustering was performed again with four clusters on the first cluster because it 
contained voxels of both the background and hypointense signal. After the algorithm 
converged again, the first two clusters were merged to represent the background and ventilation 
defects, and the last two clusters were merged to represent the hypointense signal. Combining 
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these two new clusters with the three previous clusters provided a 3He cluster map with five 
distinct clusters. 
 
Seeded Region Growing 
The proton images were segmented using seeded region growing.25 Before the algorithm was 
applied, the proton images were preprocessed using a two-dimensional radially symmetric 
low-pass Gausian filter of size 15 X 15 and σ = 2.0 in order to prevent algorithm leakage. After 
filtering, the images were binarized using a threshold to create a mask of the lungs; the 
threshold was set to half the maximum intensity of the first K-means cluster 
(background/ventilation defect) obtained from the 3He image clustering. The initial seeds were 
automatically selected by finding 20 vertically adjacent pixels within each of the lungs of the 
binary mask. Using these seeds as the starting point, the algorithm checks the boundary 
conditions of the labelled voxels and their neighboring voxels. When a labelled voxel touches 
an unlabeled voxel (3), the algorithm determines the difference (4) δ(x) between that voxel and 
the labelled voxels. 
𝑇 = { 𝑥 ∉ ⋃ 𝐴𝑖 | 𝑁(𝑥) ∩ ⋃ 𝐴𝑖  ≠  ∅ }
𝑛
𝑖=1
𝑛
𝑖=1      (3) 
where T is all the voxels that are not labelled, N (x) are the neighboring voxels to voxel x, and 
Ai is the set of labelled voxels. 
𝛿(𝑥) = |𝑔(𝑥) − mean
𝑦∈ 𝐴𝑖(𝑥)
[𝑔(𝑦)]|      (4) 
where g(x) is the signal intensity of voxel x, g(y) is the signal intensities of all labelled voxels 
within the region. Once the difference between the labelled voxels (Ai) and the target voxel 
(𝑥 ∈ 𝑇) has been calculated, the algorithm weighs the difference to determine if that voxel 
should be labelled. If the voxel’s intensity is not different from the mean voxel intensity of the 
labelled voxels, the target voxel is added to the labelled voxels (𝑥 ∈  𝐴𝑖). These steps are then 
continuously iterated until all of the available voxels are labelled. Finally, a morphological 
closing algorithm is used to fill in any gaps within each lung. 
 
ADC Segmentation 
The ADC images were segmented by applying masks to the raw images. These masks were 
generated by applying a 2-D Hanning window to the original k-space images to improve the 
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signal-to-noise ratio between the lungs and the background. Once filtered, the masks were 
generated by applying an intensity threshold to the image to separate the lungs from the 
background. Clean up of the masks was performed manually using MATLAB. 
 
CT Segmentation 
The inspiration and expiration CT images were segmented using an automatic algorithm within 
Pulmonary Workstation 2.0 (VIDA Diagnostics., Coralville, IA). This algorithm26 produces 
masks for each lung using an optimal thresholding27 technique. These masks were then applied 
to the original CT images to segment the lungs. 
 
Image Registration 
Figure 2 outlines the registration pipeline. Briefly, the 3He and 1H MR images were registered 
using a landmark based algorithm.28 The inspiration CT was registered to the expiration CT 
using an affine registration algorithm with a deformable step provided by the NiftyReg 
package.29 Before registration to the 3He and 1H MR images, the CT images and the ADC maps 
were resized and resampled to the 1H MR image dimensions using a built-in MATLAB 
function with nearest-neighbor interpolation. CT to 1H MR co-registration was performed 
using modality-independent neighborhood descriptor (MIND) deformable registration.30 The 
registration of the ADC maps to the 3He cluster maps was performed using a built-in MATLAB 
intensity based rigid registration algorithm.  
 
 
Figure 2: Graphical representation of the registration pipeline used to co-register all of the MR 
and CT images. 
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Landmark based Registration 
3He to 1H co-registration followed geometric operations to transform the images given N 
landmarks Ln’ {n=1,2,….,N} in the 
3He image that corresponded to the same number of 
landmarks Ln in the proton image. Ln’ = {
𝑗′𝑛
𝑖′𝑛
} and Ln = {
𝑗𝑛
𝑖𝑛
} denote the location of each landmark 
in the 3He and 1H images respectively. The ideal transformation was determined using a simple 
mean-squared distance cost function (5). 
𝐶 =  
1
𝑁
∑ ‖𝐿′𝑛 − 𝑇(𝐿𝑛)‖
2𝑁
𝑖=1      (5) 
Where T(Ln) is the geometric transform of the proton image landmarks (6) 
𝑇(𝐿𝑛) = 𝑠 [
cos 𝜃 −sin 𝜃
sin 𝜃 cos 𝜃
] [
𝑗𝑛
𝑖𝑛
] + [
∆𝑗
∆𝑖
]    (6) 
Where s is the scaling factor, ∆i and ∆j are the translation (i is the x-direction and j is the y-
direction), θ is the clockwise rotation angle. By substituting the transformation function (6) 
into the cost function (5), we can compute the transform by solving this cost function (7). 
𝐶 =  
1
𝑁
∑ [(𝑗′𝑛 − 𝑠 𝑗𝑛 cos 𝜃 + 𝑠 𝑖𝑛 sin 𝜃 − ∆𝑗)
2 + ( 𝑖′𝑛 − 𝑠𝑗𝑛 sin 𝜃 −  𝑠𝑖𝑛 cos 𝜃 − ∆𝑖)
2]𝑁𝑖=1       (7) 
 
Intensity based rigid registration 
ADC to 3He co-registration was accomplished by minimizing the mean square error metric 
between the two images (8). 
min
1
𝑁
∑ 𝐸𝑖𝑗
𝑁
1        (8) 
The error metric is calculated as the square of the difference between each pixel of the two 
images (9).  
𝐸𝑖𝑗 =  (𝐼1(𝑖, 𝑗) − 𝐼2(𝑖, 𝑗))
2
      (9) 
Where Eij is the error metric, I1 (i, j) is the intensity of the pixel at the location ij in the first 
image, and I2 (i, j) is the intensity of the pixel at the location ij in the second image. 
 
Nifty Registration 
To register the CT images, the affine registration algorithm starts by dividing both the reference 
and warped images into sets of blocks of equal size. A symmetric block matching approach is 
used to find blocks of voxels in the warped image that correspond to blocks of voxels in the 
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reference image. When the normalized cross correlation (NCC) (10) is maximized for a set of 
blocks, those blocks are considered matching. 
𝑁𝐶𝐶 =  
1
𝑁
∑
[𝑏𝑟(?⃗?)− 𝜇𝑏𝑟][𝑏𝑓(?⃗?)− 𝜇𝑏𝑓]
𝜎𝑏𝑟  × 𝜎𝑏𝑓
?⃗?∈ 𝑏𝑟     (10) 
Where N is the number of voxels in the block, µ and σ are the mean and standard deviation of 
the block, and br and bf are the blocks from the reference and warped image respectively. This 
block matching approach creates two sets of registered points {𝐶𝐼→𝐽} and {𝐶𝐽→𝐼} to account 
for both transformation directions. Once all the corresponding points are defined, the 
transformation parameters for these points are calculated using a least trimmed squares (LTS) 
regression method. The block matching and LTS regression are repeated in a coarse-to-fine 
fashion by starting with large blocks and moving toward smaller blocks. 
 
MIND Registration 
This algorithm first creates a descriptor for each voxel which defines the similarity between 
that voxel and its surrounding neighborhood (11) 
𝑀𝐼𝑁𝐷(𝐼, 𝑥, 𝒓) =  
1
𝑛
exp (−
𝐷𝑝(𝐼,   𝑥 ,𝑥+𝒓)
𝑉(𝐼 ,𝑥)
)       𝒓 ∈ 𝑅     (11) 
where Dp (I, x, x + r) is the distance between the voxel of interest and each of its neighboring 
voxels, V (I, x) is the noise variance of the neighborhood surrounding the voxel, and r is the 
search region. Once these descriptors are generated, it measures the similarity of each 
descriptor for the stationary IH and the moving image ICT (12). 
𝑆(𝑥) =  
1
|𝑅|
∑ |𝑀𝐼𝑁𝐷(𝐼𝐻, 𝑥, 𝒓) − 𝑀𝐼𝑁𝐷(𝐼𝐶𝑇 , 𝑥, 𝒓)|𝒓∈𝑅      (12) 
Using the similarity between these descriptors, the algorithm performs a deformable 
registration of the two images by trying to minimize the cost function (13) 
𝑎𝑟𝑔 min
𝑢
∑ 𝑆(𝐼𝐻(𝒙), 𝐼𝐶𝑇(𝒙 + 𝒖))
2
+ ∝ 𝑡𝑟 (∇𝒖(𝒙)𝑇∇𝒖(𝒙))
2
𝑥    (13) 
where the first section is the similarity term for the two images, the second section is the 
deformation field regularization term, and the deformation field 𝒖 = (𝑢, 𝑣, 𝑤)𝑇 is defined by 
(14). 
𝑢 = 𝑥′ − 𝑥 = 𝑞1𝑥 +  𝑞2𝑦 +  𝑞3𝑧 +  𝑞10 − 𝑥 
𝑣 = 𝑦′ − 𝑦 = 𝑞4𝑥 +  𝑞5𝑦 +  𝑞6𝑧 + 𝑞11 − 𝑦             (14) 
𝑤 = 𝑧′ − 𝑧 = 𝑞7𝑥 +  𝑞8𝑦 +  𝑞9𝑧 +  𝑞12 − 𝑧 
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where the transformed location of voxel 𝒙 = (𝑥, 𝑦, 𝑧)𝑇 is 𝒙′ = (𝑥′, 𝑦′, 𝑧′)𝑇, and {𝑞1,
𝑞2 , … 𝑞12} are the transformation parameters. The deformation is optimized using a Gauss-
Newton optimization method, and the optimization is solved using successive over-relaxation. 
Registration accuracy was determined using a Dice Similarity Coefficient (DSC). 
 
Multi-Parametric Response Maps 
We used MATLAB (Mathworks, Natick, MA, USA) to generate multi-parametric response 
maps from the co-registered voxels by assigning each voxel on mPRM to a group based on the 
values of the co-registered voxels. Table 1 describes the criteria for each voxel label. An 
expiration CT threshold of -856HU was used to determine gas-trapping, and an inspiration CT 
threshold of -950HU was used to determine emphysema.13 An ADC threshold of 0.3 cm2/s was 
used based on previously22,31 determined values from healthy and mild to severe COPD 
subjects. An ADC value of 0.0 cm2/s represented unventilated regions in the ADC map.  
 
Table 1: mPRM grouping criteria for co-registered 3He Cluster maps, 3He ADC maps, and 
inspiration or expiration CT 
Group He MRI SV Expiration CT Inspiration CT He MRI 
ADC 
Code 
1 Ventilated ≥ -856 HU ≥ -950 HU <0.3 cm2/s and 
>0.0 cm2/s 
Green 
2 Ventilated ≥ -856 HU ≥ -950 HU ≥0.3 cm2/s or 
=0.0cm2/s 
Yellow 
3 Ventilated < -856 HU < -950 HU <0.3 cm2/s and 
>0.0 cm2/s 
Dark 
Yellow 
4 Ventilated < -856 HU < -950 HU ≥0.3 cm2/s or 
=0.0cm2/s 
Orange 
5 Unventilated ≥ -856 HU ≥ -950 HU NA Bright 
Red 
6 Unventilated < -856 HU < -950 HU NA Dark Red 
ADC: apparent diffusion coefficient; HU: Hounsfield units 
 
Study Subjects, Spirometry and Other Tests 
Five ex-smokers without COPD and 15 ex-smokers with COPD provided written informed 
consent to a study protocol (registered at clinicaltrials.gov as NCT02279329) approved by a 
local research ethics board and underwent pulmonary function tests,32 MRI and CT. 
Hyperpolarized 3He static ventilation (SV) and diffusion-weighted MRI were performed, as 
well as CT at full inspiration and full expiration breath hold scans as previously described.21 
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RESULTS 
 
Subject Demographics 
Subject demographics for five ex-smokers, five subjects with GOLD I COPD, five with GOLD 
II COPD, and five with GOLD III COPD (Table 2). 
 
Table 2: Subject demographics and pulmonary function test data 
Parameter  
Mean (±SD) 
Ex-smokers 
n=5 
GOLD 1 
n=5 
GOLD 2 
n=5 
GOLD 3 
n=5 
Age, yrs 67 (12) 74 (5) 73 (9) 74 (7) 
Male, n 2 5 3 4 
BMI kg/m2 30 (4) 28 (3) 27 (2) 27 (2) 
Pack Years 28 (9) 28 (18) 44 (33) 39 (37) 
FEV1 %pred 99 (15) 97 (9) 62 (13) 39 (7) 
FVC %pred 93 (15) 111 (14) 87 (8) 73 (14) 
FEV1/FVC % 80 (4) 64 (4) 52 (11) 40 (6) 
TLC %pred 95 (9) 111 (10) 116 (14) 114 (20) 
RV/TLC % 42 (7) 42 (5) 49 (9) 58 (13) 
DLCO %pred 84 (13) 86 (24) 70 (21) 53 (13) 
BMI: Body mass index; FEV1: Forced expiratory volume in one second; FVC: Forced vital 
capacity; TLC: Total lung capacity; RV: Residual volume; DLco: Diffusing capacity for carbon 
monoxide; %pred: Percent predicted. 
 
Image Co-registration 
Figure 3 displays a representative set of registered images for a subject with GOLD grade 1 
COPD. In the 20 subjects presented, we achieved a DSC of 83 ± 4 % for the ADC map to 1H 
image registration and 92± 3% for the CT image to 1H image registration.  
 
Figure 3: Comparison of MRI and CT images in a GOLD Grade 1 subject  
A) 3He ventilation cluster map, B) ADC map, C) Expiration CT, D) Inspiration CT 
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Multi-Parametric Response Maps 
Figure 4 shows multi-parametric response maps for a representative ex-smoker, GOLD 1, 
GOLD 2, and GOLD 3 subject. As COPD severity increases, the volume of normal voxels 
(group 1) decreases, the volume of normal voxels with abnormal ADC (group 2) increases, and 
the volume of abnormal voxels (groups 5 & 6) increases. mPRM generated from expiration 
CT show increases in ventilated, gas-trapping voxels (groups 3 & 4) with increasing COPD 
severity; while mPRM generated from inspiration CT show limited change in ventilated, 
emphysematous voxels (groups 3 & 4) with increasing COPD severity. These results are 
summarized in Table 3. 
Figure 4: Multi-parametric Response Maps (mPRM) from co-registered 3He ventilation map, 
3He ADC map, and inspiration/expiration CT images for representative subjects. 
Ex-smoker without COPD (A, E), GOLD 1 (B, F), GOLD 2 (C, G), GOLD 3 (D, H). 
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Table 3: Voxel Group Distributions 
Mean ± SD Ex-smokers 
n=5 
GOLD 1 
n=5 
GOLD 2 
n=5 
GOLD 3 
n=5 
Group 1EXP (%) 62 ± 7.9 32 ± 13 30 ± 24 12 ± 8.3 
Group 1INSP (%) 63 ± 7.6 37 ± 11 34 ± 25 15 ± 8.8 
Group 2EXP (%) 31 ± 7.9 46 ± 8.2 33 ± 8.2 33 ± 6.5 
Group 2INSP (%) 32 ± 7.8 54 ± 11 44 ± 14 47 ± 9.0 
Group 3EXP (%) .75 ± 1.1 4.8 ± 3.3 3.8 ± 3.0 4.0 ± 2.5 
Group 3INSP (%) 0 ± 0 .08 ± .09 .14 ± .09 .16 ± .19 
Group 4EXP (%) .43 ± .74 8.1 ± 7.5 12 ± 14 16 ± 9.1 
Group 4INSP (%) 0  ± 0 .16 ± .16 1.1 ± 2.1 .85 ± 1.4 
Group 5EXP (%) 5.5 ± 2.8 8.4 ± 4.5 15 ± 8.7 23 ± 7.1 
Group 5INSP (%) 5.6 ± 2.9 8.9 ± 5.0 19 ± 9.8 34 ± 9.0 
Group 6EXP (%) .06 ± .12 .53 ± .63 5.0 ± 7.3 13 ± 9.7 
Group 6INSP (%) 0 ± 0 .05 ± .09 1.1 ± 2.3 1.9 ± 3.3 
 
NEW OR BREAKTHROUGH WORK TO BE PRESENTED 
We developed a segmentation and registration pipeline for the generation of multi-parametric 
response maps using hyperpolarized gas MRI and CT. The proposed approach provides 
promising results as a new metric for phenotyping COPD. 
 
DISCUSSION AND CONCLUSION  
mPRM provides a way to combine the functional and structural information of multiple 
imaging modalities. However, a robust image processing pipeline is required to generate these 
maps. Segmentation and registration errors may result in voxel mislabeling thereby reducing 
the mPRM differentiation ability. Therefore, we developed and evaluated an image processing 
pipeline to generate mPRM. The proposed pipeline provides moderate registration accuracy 
between the imaging modalities, but a large amount of user interaction hinders efficient 
implementation of the pipeline. Future work will focus on improving the registration to 
increase the overall accuracy of mPRM, and on automating the image segmentations to reduce 
mPRM generation time and increase efficiency. 
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